Prevention and treatment of hemodialysis access thrombosis by Smits, Johannes Henricus Maria
PREVENTION AND TREATMENT OF HEMODIALYSIS
ACCESS THROMBOSIS
J.H.M. Smits
Cover design: Sithabile Mlotshwa; “Heart Beat” and “Life Giver”, 2001
Layout: Audiovisuele Dienst, UMC, Utrecht
Printing: Budde Elinkwijk Grafische Producties B.V., Nieuwegein
Prevention and treatment of hemodialysis access thrombosis
J.H.M. Smits; Universiteit Utrecht, Faculteit Geneeskunde
Thesis Utrecht University – with a summary in Dutch
ISBN 90-393-2837-4
Subject headings: Vascular access, Hemodialysis, Thrombosis, Prevention, Treatment
 2001 J.H.M. Smits, Utrecht, The Netherlands
All rights reserved. No part of this publication may be reproduced, stored in retrieval systems,
or transmitted in any form or by any means, mechanically, by photocopying, by recording or
otherwise without the permission of the author.
PREVENTION AND TREATMENT OF HEMODIALYSIS
ACCESS THROMBOSIS
PREVENTIE EN BEHANDELING VAN HEMODIALYSE VAATTOEGANG
TROMBOSE
(met een samenvatting in het Nederlands)
Proefschrift
ter verkrijging van de graad van doctor aan de Universiteit Utrecht
op gezag van de Rector Magnificus, Prof. Dr. W.H. Gispen
ingevolge het besluit van het College voor Promoties
in het openbaar te verdedigen op
dinsdag 30 oktober 2001 des middags te 2.30 uur
door
Johannes Henricus Maria Smits
geboren op 8 augustus 1971 te Deurne
Promotor: Prof. Dr. H.A. Koomans
Co-promotor: Dr. P.J. Blankestijn
Studies in this thesis were supported by a grant from the Dutch Kidney Foundation
(C97.1643). Publication of this thesis was supported by Transonic Systems, Inc., Ithaca, NY,
USA, Merck Sharpe & Dohme B.V., Janssen-Cilag B.V., and GlaxoWellcome B.V. Financial
support by the Dutch Kidney Foundation and the Netherlands Heart Foundation for the







bFGF basic fibroblast growth factor
CDF color Doppler flow 
CV central vein
DL double-lumen
DSA digital subtraction angiography
ESRD end-stage renal disease
FV femoral vein
HD hemodialysis
INR international normalized ratio
K/DOQI kidney disease outcomes quality initiative
LA lupus anticoagulant
MAP mean arterial pressure
(CE)-MRA (contrast-enhanced) magnetic resonance angiography
NKF-DOQI national kidney foundation - dialysis outcome quality initiative
NS not significant
PIA intra-access pressure
PDGF platelet-derived growth factor
PTA percutaneous transluminal angiography
PTFE polytetrafluoroethylene
Qa access flow
SBP systolic blood pressure
SCVIR society of cardiovascular and interventional radiology
SEM standard error of the mean
SL single-lumen
URR urea reduction ratio
VP venous pressure
vWF von Willebrand factor
Contents
Chapter 1 Introduction
Chapter 2 Outline of the thesis
Chapter 3 Graft surveillance: venous pressure, access flow, or the combination?
Chapter 4 Hemodialysis access imaging: comparison of flow interrupted contrast-
enhanced MR angiography versus digital subtraction angiography
Chapter 5 Short- and long-term functional effect of percutaneous transluminal
angioplasty in hemodialysis vascular access
Chapter 6 Percutaneous thrombolysis of thrombosed hemodialysis access grafts:
comparison of three mechanical devices
Chapter 7 Single-lumen versus double-lumen catheters for temporary hemodialysis
access: a randomized prospective single center trial
Chapter 8 Coagulation and hemodialysis access thrombosis
Chapter 9 General discussion







hoofdstuk 01  09-10-2001  10:05  Pagina 1
2Chapter 1
hoofdstuk 01  09-10-2001  10:05  Pagina 2
Introduction
“As we did not know at all how our first patient would react to the dialysis we started
with repeatedly dialysing small portions of blood. In the end we succeeded in keeping the
percentage of urea at the same level for 26 days, after that no more serviceable veins were
available.” The 29-year old patient died 34 days after initiating her dialysis treatment.
Since those problematic but promising hemodialysis sessions with the first artificial kid-
ney performed by Dr. Willem J. Kolff in the Municipal Hospital of Kampen, The
Netherlands, in 1943, many of the hemodialysis-related problems have been solved [1].
Kolff ’s first effective dialysis treatment of an end-stage renal disease (ESRD) patient came
to an end because of problems gaining access to the bloodstream. After depleting the
readily accessible veins and disappointing artery punctures, no adequate access to the
bloodstream could be established for transporting blood to and from the artificial kidney
[1]. “We believe to be able to keep patients suffering from uremia and anuria alive so long
as blood vessels for punction are available”, he wrote. Since those early dialysis pioneering
days, dialysis equipment has improved dramatically. Also, attempts were made to sustain
and improve access to the blood stream. However, it was not until the 1960s when the
first papers appeared describing novel methods for gaining access to the blood stream
[2,3], that long-term hemodialysis would become a reality. In 1966, Brescia and Cimino
published an article describing an arteriovenous (AV) fistula between the radial artery
and cephalic vein, which could function as a vascular access [4]. First, they made an anas-
tomosis between the artery and the vein. Then, the day after surgery, the vein down-
stream from the anastomosis was engorged by a tourniquet, and therefore allowed for
cannulation to gain access to the blood stream. The investigators noted that with time,
the vessels became “even more prominent and thicker-walled, making venepuncture even
easier” [4,5]. Because of its low infection and thrombosis rate, the Brescia-Cimino
(radio-cephalic) fistula is still regarded as the first choice for the creation of a vascular
access for hemodialysis [6]. Other forms of AV fistula include the brachio-cephalic fistula
and the transposed brachio-basilic fistula [7-9]. Nowadays, AV fistulae are allowed to
mature for a period of at least 1 month until there is sufficient dilatation and “arterializa-
tion” on physical examination [5,6]. Unfortunately, not all patients have suitable vessels
to construct an AV fistula, mainly because of their insufficient caliber or sclerosis due to
prior venipunctures. Therefore, a modification of the AV fistula was found in construct-
ing an interposition graft between an artery and a vein. The interposition AV graft could
then function as a vascular access by itself. Several materials were studied on their ability
to function as an AV graft, like bovine carotid artery grafts, autogenous and homologous
vein grafts, and human umbilical cord grafts [10-15]. AV grafts of synthetic materials
were also developed to function as vascular access [16]. Nowadays, AV grafts are predom-
inantly manufactured from expanded polytetrafluoroethylene (PTFE).
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Unfortunately, these PTFE AV grafts show a thrombosis rate of 0.5 - 2.5 per patient-year
[6,17-20] resulting in considerable morbidity and even mortality [21,22]. For the United
States, it was calculated that vascular access morbidity is responsible for an estimated
annual cost of close to $1 billion and accounts for 17 - 25% of all dialysis patients hospi-
talizations [23-26]. Because of these complications the NKF-K/DOQI guidelines on vas-
cular access suggest that vascular access using AV grafts may only be considered, if it is
not possible to establish either a radio-cephalic or a brachio-cephalic AV fistula [6,27].
Despite the higher rate of thrombosis and its subsequent morbidity, an increasing num-
ber of patients depend on an AV graft. In some populations in the United States, AV
grafts account for as many as 83% of access placements [28]. Because of the increasing
age of the hemodialysis patients, establishment of an AV fistula in those patients becomes
difficult due to insufficient vessels. Also, the number of patients with end-stage renal dis-
ease (ESRD) requiring hemodialysis is increasing worldwide [29]. In The Netherlands
the use of AV grafts is increasing at the expense of AV fistulae [30]. As a consequence,
patients and physicians alike are more frequently confronted with vascular access com-
plications, particularly thrombosis.
This thesis focuses on the prevention and treatment of hemodialysis access thrombosis.
AV graft thrombosis: cause and prevention
In almost all cases, thrombosis is associated with the presence of one or more stenoses in
the AV graft. Usually, they are located at or near the venous anastomosis of the AV graft
or elsewhere in the venous outflow tract [31-34]. They show the typical histology of inti-
mal hyperplasia [35,36]. The presence of a stenosis results in both anatomical (for
instance reduction of the vessel lumen) and functional changes. These functional
changes include an increase in resistance and pressure gradient over the stenosis, and a
subsequent decline in access blood flow. The logical approach would be prevention of the
development of intimal hyperplasia. At present, this is not possible in clinical practice,
although interesting experimental work is being conducted [37,38]. Therefore, the sec-
ond best approach is identifying patients at risk of thrombosis and referring them for
corrective intervention. This indeed reduces thrombosis rate dramatically and prolongs
vascular access patency [31,39-45]. Percutaneous transluminal angioplasty (PTA) or sur-
gical correction can be considered for elective intervention [6,46].
Thrombosis rate can also be reduced by decreasing coagulability. Both dipyridamole and
coumarin reduced the risk of thrombosis in patients with PTFE grafts [47,48]. Although
specific antiproliferative effects of these agents can not be excluded, it is possible that
these drugs only bring the risk for thrombosis to a lower level of flow.
All presently used vascular access monitoring methods focus on detecting the anatomical
and/or the functional changes that are induced by stenosis.
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Monitoring techniques to detect accesses at risk of thrombosis
Physical examination
Physical examination includes inspection, palpation, and possibly auscultation [6].
Collateral vessel formation or edema of an extremity may indicate the presence of steno-
sis. Palpation and auscultation can be useful for detecting stenosis. Trerotola et al.
claimed that it is possible to rule out low flows by palpation alone [49]. Safa et al. used
auscultation as tool in a surveillance program [33]. Others have included physical exami-
nation in monitoring programs as well [18,50].
Although physical examination is easily performed and inexpensive, many clinicians will
feel that its value is limited, because results are highly investigator dependent.
Venous pressure (VP)
As a result of the presence of a stenosis, resistance over the outflow tract increases and the
pressure upstream from the stenosis will rise. Most dialysis devices are capable of meas-
uring the venous drip chamber pressure, which is an indirect derivative of the true intra-
access pressure. Schwab et al. described a method to monitor vascular access by
evaluating venous drip chamber pressure with a pump flow rate of 200 - 225 mL/min,
the so-called dynamic venous pressure. When PTA was done of stenoses in patients who
had a dynamic VP > 150 mmHg, thrombosis rate was 0.20 per patient-year. This study
included patients with AVF and PTFE grafts [43]. Cayco et al. used dynamic VP for sur-
veillance of grafts and reported a thrombosis rate of 0.29 events per year [18].
Besarab et al. further refined the concept [39] and recently introduced the equalized
intra-access VP measurement corrected for height and mean arterial pressure
(eqPIA/MAP) [51]. EqPIA/MAP ≥ 0.5 was associated with hemodynamically significant
(i.e. low flow) and angiographically confirmed stenosis. They showed that treating
stenoses in patients identified by PIA/SBP resulted in a thrombosis rate of 0.17 per
patient-year [39]. This study group consisted of both AV grafts and fistulae.
Access flow
Increased resistance due to stenosis causes low flow, which has been shown to be predic-
tive for thrombosis in early studies (reviewed in [52,53]). A variety of devices has now
been developed which are capable of measuring or calculating flow during dialysis treat-
ment [54-60]. So far, the ultrasound dilution technique seems to be the best-validated
technique [53,54].
Several questions, however, have not been addressed yet. The optimal frequency of meas-
urements and the optimal threshold level for intervention have not been determined. It
was shown that in a group of patients with AV grafts monitored by venous pressures,
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almost all thromboses occurred within 2 months after measurements in patients with a
flow < 600 mL/min [61]. Others have suggested 500 mL/min [62], 650 ml/min [46] or
750 ml/min [20] as threshold level, when flow is measured every 4 to 8 weeks. May et al.
reported that relative risk of thrombosis in grafts within 3 months after measurements
was 1.36, 1.51 and 1.67 when flow was 850, 750 and 650 mL/min respectively [63].
Venous pressure did not predict thrombosis. Sands et al. found that patients with PTFE
grafts and flow rates < 800 mL/min had a 93% incidence of thrombosis during the 6
months following the measurements [64]. These data seem to support the idea that by
decreasing the frequency of flow assessment the cut-off value indicating increased risk
for thrombosis increases.
This points to another deficiency in our knowledge. Basically, there are no data on the
natural history of stenosis development and therefore on the change of risk of thrombo-
sis over time. It seems likely that the absolute value of flow is related to the risk of throm-
bosis, whereas the decrease in flow over time reflects development of stenosis. In a recent
study it was shown that especially a decrease in flow over time was predictive for immi-
nent thrombosis [65]. Factors that influence the speed of development of stenosis are
hardly known. It is conceivable that patients with initially high but decreasing flow need
to be evaluated more frequently than patients with stable flow.
Some investigators have measured flow in AV fistulae. Flow may be as low as 130 mL/min
and as high as 3600 mL/min. Bouchouareb et al. reported in 9 of their 90 patients with
native arm fistulae flows > 2000 mL/min [66]. Recently, it was argued that flow measure-
ment in AV fistulae with the ultrasound dilution method poses problems [54], because
needle placement is very critical. The arterial needle has to be placed in the main branch.
AV fistulae may have side branches. Placement of the needles in two minor branches
makes it impossible to measure flow.
More important is the question whether it is at all useful to monitor the functional status
of the AV fistulae. Once fully matured, thrombosis is a rare complication. Besarab et al.
already noted that venous pressure monitoring was not useful in native accesses [39].
Sands et al. showed that monthly flow measurements in AV fistulae resulted in a minimal
reduction of the already very low thrombosis rate [20].
Recirculation
Recirculation occurs when dialyzed blood that comes out of the “venous” needle of the
extracorporeal circuit is taken up again through the “arterial” needle bypassing the sys-
temic circulation.
Several methods are available to measure recirculation. Using urea samples poses serious
methodological problems [67,68], and has poor stenosis predictability [69]. When com-
pared with a method using a non-urea indicator, it became clear that values of > 10%
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mean true access recirculation in most cases. Many devices are capable of measuring
recirculation using non-urea based methods [55,58,59,67,70-72]. Most devices have been
clinically validated and are able to differentiate between cardiopulmonary and true access
recirculation.
Because recirculation only occurs when spontaneous blood flow through the graft
approaches the blood flow through the extracorporeal circuit [73] it should be consid-
ered at best as a late sign for access dysfunction.
Identifying stenosis location: vascular access imaging
The gold standard for vascular access imaging is contrast angiography. However, its use
as a singular prospective monitoring tool is not possible for obvious reasons.
Color Doppler flow (CDF) imaging enables the physician to non-invasively obtain an
anatomical and a functional image of the access. Several studies have shown a good cor-
relation between stenosis detection by Color Doppler imaging and angiography [74-78].
Sands et al. reported a thrombosis rate of 0.19 in patients referred for PTA when a ≥ 50%
stenosis was detected by CDF imaging, whereas it was 1.26 per patient-year in controls
[79].
Two other recent studies are worth mentioning. Lumsden et al. randomized patients with
greater than 50% stenosis to have either a PTA or no PTA and found that outcome did
not differ [80]. Later the same authors re-analyzed their data and reported that patency
did improve but only in grafts without prior angioplasty or thrombosis [81].
Magnetic resonance angiography (MRA) is able to quantify flow [82] and to provide
anatomical information in AV fistulae [83]. However, anatomical information still leaves
much to be desired with the current phase-contrast and time-of-flight MR techniques,
even when the image is enhanced by gadolinium contrast [84,85]. MRA guided angio-
plasty was performed in a limited number of patients [86,87]. Whether MRA will indeed
turn out to be the ideal one-stop-shop approach for both diagnosis and treatment of
grafts at risk of thrombosis, remains to be established.
Stenosis correction and prevention of restenosis
Radiological series report a patency of 6 months after PTA of 40 - 60% and of 20 - 40%
after thrombolysis combined with PTA [31,40,45,88]. These results are not convincingly
different from surgical treatment. Data on comparison of radiological series with surgi-
cal treatment mainly come from uncontrolled or retrospective studies [88]. Also stent
placement did not result in clear improvement of results, except for central venous
stenoses [89]. Marston et al. evaluated 123 cases of PTFE graft thrombosis who were ran-
domized to surgical or radiological management [90]. Patency in the surgical group was
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significantly better than in the other group, 36% and 25% versus 11% and 9% after 6 and
12 months respectively. Nevertheless, many clinicians will feel that PTA is the primary
choice of treatment of stenoses. Surgical correction often means the creation of a new
anastomosis. For a particular graft this can only be done once or a few times, whereas
PTA of a lesion can be done repeatedly [40]. It can be carried out without regional or
general anesthesia and it is usually done as an outpatient procedure.
Restenosis is an imminent danger after PTA. PTA injures the vessel wall. The proliferative
response to this injury is implicated as cause for restenosis. Some years ago, the hypothe-
sis was tested that increasing the luminal diameter by sharp and regular endovascular
surgical incisions instead of circular dilatation by a conventional balloon, would increase
the success of the angioplasty [91]. Indeed, in an animal model the cutting balloon pro-
duced less intimal proliferation than a standard balloon [91,92]. Early results in coronary
arteries seem to indicate that this hypothesis is indeed worth studying in humans
[93,94]. Limited, uncontrolled data in hemodialysis patients indicate that this device may
be useful in clinical practice [95].
A most exciting development is the emerging potential of gene therapy for the treatment
of vasculoproliferative disease, including possible pharmacological inhibition of resteno-
sis after angioplasty [96-98]. It has been shown that vascular smooth muscle cell prolifer-
ation and lesion formation can be prevented by the blockade of genes regulating cell
cycle progression. It seems that hemodialysis AV grafts offer an attractive in vivo model
for this therapy, because they are relatively easily accessible and periodic imaging during
follow up is not a great burden to the patient.
Treatment of the thrombosed access
Despite vascular access surveillance, thrombosis still occurs [18,20,32,33,39,43,50,79]. No
consensus has been established to resolve thrombosis in AV fistulae [6]. For AV grafts,
there are basically two ways to restore the patency after thrombosis: by surgical thrombec-
tomy or radiologically by pharmacomechanical or mechanical thrombolysis. Comparative
studies show conflicting results [17,99-103]. When a surgical thrombectomy is performed,
the only way to treat a possible underlying stenosis is to revise the access. In many cases
this means that the (venous) anastomosis is constructed more proximally. As a conse-
quence, after several surgical revisions there is no more space to construct an anastomosis.
The advantage of radiological thrombolysis is the possibility to evaluate the access after
the thrombolytic procedure by angiogram and to treat the underlying stenosis directly
after thrombolysis by angioplasty [99]. There is no need to revise the anastomosis and
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angioplasty can be performed repeatedly to preserve the access [40].
Of course, while the patient is waiting for restoration of the access, there is still the need
for dialysis and therefore for an access. One possibility is to insert a temporary catheter in
a large vein, i.e. a femoral or internal jugular vein. These catheters can also be used to act
as an access, while they are waiting for the first construction of an access, or while in need
for an acute access.
In summary, since the introduction of the AV fistula and the PTFE AV graft for vascular
access, little improvement in vascular access has been made. Unfortunately, not all
patients can receive the preferred AV fistula, and depend on PTFE AV grafts instead. The
main problem with these AV grafts is thrombosis, mostly caused by intimal hyperplasia.
This leads to a huge burden for patient, nurses and physicians. Not only does it require
salvage of the access, but also in the meantime the patients receives other types of access-
es, in most cases a temporary catheter, that can lead to insufficient dialysis and infection.
Therefore, it is paramount to prevent thrombosis. In the unfortunate case that thrombo-
sis does occur, all has to be done to resolve the thrombosis as soon as possible, and to
reestablish a patent access.
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Outline of the thesis
Vascular access thrombosis is associated with stenosis, particularly in polytetrafluoroeth-
ylene (PTFE) arteriovenous (AV) grafts [1]. These stenoses cause an increased resistance
over the access tract. Because the graft has no auto-regulating capacities, this leads to a
decrease in vascular access blood flow (Qa), and to an increase in intra-access pressure,
which is commonly expressed as venous pressure (VP) [2,3]. Consequently, both param-
eters (i.e. Qa and VP) can be used as predictors for impending vascular access failure [4].
Theoretically, Qa provides more information about the vascular access than the intra-
access VP measurement, because it provides information about the total access tract. The
VP measurement only provides information about the access upstream from the venous
needle. We have to realize that surveillance using VP is without extra cost and results are
very easy to obtain. In chapter 3 we investigated whether Qa measurements are better
than VP measurements in identifying patients at risk for thrombosis. Furthermore, we
looked whether referral of patients for corrective interventions (stenosis treatment with
percutaneous transluminal angioplasty, PTA) based on Qa measurements alone or on the
combination of VP and Qa reduces thrombosis rate more than referral based on VP
alone.
After the clinical detection of an impaired vascular access it is imminent to localize and
treat a stenosis before thrombosis occurs [5]. Conventional imaging of the access mainly
consists of digital subtraction angiography (DSA). However, the radiation load and the
use of iodinated contrast agents needed for DSA are considered the major disadvantages
of this imaging modality. Magnetic resonance angiography (MRA) offers the opportuni-
ty to provide an image of the access without these less desirable features of DSA.
However, because of turbulent blood flow some segments of the MR image can present
as a void, especially near the anastomoses [6,7]. Even with contrast-enhancement there
are still substantial artifacts, because of the presence of flow [8]. Therefore, we designed a
flow-interrupted contrast-enhanced MR imaging sequence. In chapter 4 we compared
this novel MRA imaging of the vascular access with DSA.
After detection of a failing access, it is important to intervene before thrombosis occurs
[9]. The common approach for intervention nowadays is PTA [4,10]. Several studies
demonstrated that the overall survival of the access can be prolonged by repetitive PTA
[5,11]. In chapter 5 we studied the short-term effect of PTA on Qa, Qa patterns after
PTA, and which factors had an influence on Qa after PTA.
If, despite the efforts of detecting failing accesses timely, thrombosis still occurs, the dial-
ysis patient comes in an undesirable situation. Namely, the patient cannot get access to
the hemodialysis treatment. When this happens, it is paramount to re-establish a patent
vascular access as soon as possible. This can be done by surgical thrombectomy or radio-
logically by percutaneous thrombolysis [4]. The latter has become the treatment of
18
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choice for thrombosed hemodialysis grafts [10,12,13]. In chapter 6 we compared three
devices for percutaneous thrombolysis with respect to their efficacy in removing throm-
bus from hemodialysis access grafts. Treatment should be initiated immediately after
diagnosing thrombosis [14]. In many cases this cannot be done immediately and the
patients rely on other types of accesses, mostly a temporary catheter in the internal jugu-
lar or femoral vein [15]. These catheters are also used as vascular access, when the arteri-
ovenous graft or fistula is not constructed or ready for puncture at the onset of dialysis
treatment. Basically, there are two types of temporary catheters: the single-lumen and the
double-lumen catheters. Single-lumen catheters do not allow for a continuous blood
flow to and from the dialysis machine, whereas double-lumen catheters do. Although it is
presumed that single-lumen catheters have a lower dialysis adequacy than double-lumen
catheters, this has not been formally investigated yet. In chapter 7 we present a random-
ized prospective trial comparing dialysis adequacy and overall performance in single-
lumen versus double-lumen catheters.
Not all decreases in access blood flow are related to intimal hyperplasia or stenosis for-
mation. Other causes for low access flow leading to access thrombosis have been pro-
posed. Hypotension, hypovolaemia, or external compression may be involved in these
non-stenotic thrombotic events [16]. Also, there has been a growing appreciation of the
role of increased hypercoagulability found in these patients. In chapter 8 we discuss
coagulability abnormalities in relation to haemodialysis access thrombosis.
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Abstract
Background. Increased venous pressure (VP) and decreased access flow (Qa) are predic-
tors of dialysis access graft thrombosis. VP is easily obtainable. Qa assessment requires a
special device and takes more time. Aims of our randomized multi-center studies were to
compare outcome in patients with grafts monitored by VP or Qa (study A) or monitored
by VP or the combination of VP and Qa (study B).
Methods. We performed VP measurements that consisted of weekly VP at a pumpflow of
200 mL/min (VP200) and the ratio of VP0/MAP. Qa was measured every 8 weeks with
the Transonic HD01 hemodialysis monitor. Threshold levels for referral for angiography
were VP200 > 150 mmHg or VP0/MAP > 0.5 (both at 3 consecutive dialysis sessions), or
Qa < 600 mL/min. Subsequent therapy consisted of either PTA or surgery.
Results. Total follow-up was 80.5 patient-years for 125 grafts. The vast majority of a total
of 131 positive tests was followed by angiography and corrective intervention. In study A,
the rate of thromboses not preceded by a positive test was 0.19 and 0.24 per patient-year
(P = NS) and in study B it was 0.32 versus 0.28 per patient-year (P = NS). Survival curves
were not significantly different between the subgroups.
Conclusions. These data demonstrate that standardized monitoring of either VP or Qa or
the combination of both and subsequent corrective intervention can reduce thrombosis
rate in grafts to below the recommended quality of care standard (i.e. 0.5 per patient-




hoofdstuk 03  09-10-2001  10:04  Pagina 22
Introduction
Thrombosis remains a major problem in vascular access for hemodialysis, particularly in
polytetrafluoroethylene (PTFE) grafts. It accounts for considerable morbidity and mor-
tality with an annual cost of close to $1 billion in the United States and is responsible for
17 - 25% of all hospitalizations in dialysis patients [1-3].
Thrombosis occurs at a rate of 0.5 to 2.5 events per patient-year [4-8]. In most cases
thrombosis is associated with the presence of stenoses at the venous anastomosis or in
the outflow tract [9-13]. Stenosis increases resistance over the flow tract. Because the
graft has no autoregulating capacities, blood flow (Qa) drops and venous pressures (VP)
rise. These variables have been shown to predict thrombosis. More importantly, several
studies demonstrated that referral for corrective intervention based on these parameters
can prevent thrombosis [14-18].
We and others confirmed that patients with outflow stenosis have on average a higher VP
and/or lower Qa [14,19]. However, VP did not correlate with Qa. In other words not all
patients with high VP had low Qa, indicating that not all patients who are at risk for
thrombosis can be identified by VP measurements. We also showed that inflow resistance
(that is resistance of the flow tract upstream of the venous needle) comprises a substan-
tial and very variable part of total graft resistance. Indeed, several studies have indicated
that in up to 29% of thrombosis cases, stenoses may be located in the arterial part of the
graft [13,20-23]. The inflow resistance is not reflected by VP measurements, whereas Qa
measurements are a reflection of total graft resistance. This could make VP less effective
as selection parameter for patients at risk for thrombosis than Qa. In contrast to Qa
measurements, VP can be measured by the dialysis machine, is easy to obtain and
requires little time investment. Furthermore, some studies have convincingly indicated
that the use of VP measurements as a selection variable for diagnostic and subsequent
corrective procedures, results in thrombosis rates between 0.2 and 0.4 events per patient-
year [6,14,16]. Although we provided the theoretical basis that Qa measurements are bet-
ter than VP measurements, the question is whether Qa measurements really confer
additional benefit in patients who are monitored by VP. In other words, when simple
clinical variables such as VP are used, is there any additional benefit when periodic Qa
measurements are added to the surveillance protocol?
Our hypothesis for the present studies was as follows: Qa measurements are better than
VP measurements in identifying patients at risk for thrombosis. As a consequence: refer-
ral of patients for corrective interventions based on Qa measurements alone or on the
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Patients and methods
Five dialysis centers participated in this study. All patients with a hemodialysis access
PTFE graft were eligible to enter into the study. Exclusion criteria were inability to give
informed consent and contrast allergy. Studies were approved by the Institutional Ethical
Review Committees. Informed consent was obtained from all patients.
Surveillance protocols
Two surveillance studies were conducted concurrently. In study A patients were assigned
to weekly VP measurements (Group A1) or periodic Qa measurements (Group A2). In
study B, patients were assigned to weekly VP measurements (Group B1) or the combina-
tion of VP measurements and periodic Qa measurements (Group A2). Study A was insti-
tuted in one center (Rotterdam) and study B in four. Within the centers the patients were
prospectively and at random allocated to one of the subgroups of each study (Fig. 1).
Venous pressure monitoring
Measurements were done once weekly, within the first half-hour of dialysis, and included
both dynamic and static VP measurements. When one or both measurements were posi-
tive (see Indication for referral for angiography), measurements were repeated the next
dialysis session. All centers had dialysis machines with digital pressure displays.
Maintenance and calibration was done according to the manufacturer’s recommenda-
tions on a regular basis by an experienced technician.
24
Chapter 3
Figure 1. Study design
hoofdstuk 03  09-10-2001  10:04  Pagina 24
Dynamic venous pressure
Digitally displayed dynamic VPs were assessed with a fixed pump flow set at 200 mL/min
(VP200), as described by Schwab et al. [16]. Ten subsequent readings on the dialyzer dis-
play were averaged. After the measurement the pump flow was set to the original level.
Static venous pressure
Static VP (VP0) was assessed with zero pump flow with the tubing out of the air lock in
order to avoid automatic closure of the tubing after the pump was shut off. VP0 was
divided by mean arterial pressure (MAP) to correct for blood pressure differences as
described by Besarab et al. [14]. No correction for height differences was made. MAP was
calculated by taking two times diastolic pressure plus systolic pressure divided by three.
Access flow measurement
Measurements were done every eight weeks. Qa was measured with the Transonic
Hemodialysis Monitor (Transonic Systems Inc, Ithaca, NY). The theoretical background,
bench validation and in vivo validation are described in detail in previous papers [24,25].
Periodic calibration was done by the local distributor. Qa determination consisted of the
average of three consecutive measurements. If Qa levels reached between 600 and 800
mL/min the measurement was repeated after one month. All measurements were done
with a dialyzer blood flow of more than 200 mL/min.
Indication for referral for angiography
Referral of Group A1 patients for angiography was based on three consecutive dialysis
sessions with elevated static and/or dynamic VP. Patients in Group A2 underwent
angiography when Qa fell below 600 mL/min. Indication for referral of Group B1
patients for angiography was an elevated static and/or dynamic VP, similar to Group A1.
In Group B2 an elevated static and/or dynamic VP and/or Qa below 600 mL/min were
reasons for referral. The threshold level for the static VP ratio was 0.5, according to the
method described by Besarab et al. [14]. Threshold for dynamic VP was 150 mmHg.
Angiography was done to determine presence and location of the stenosis. If a stenosis of
> 50% was present, the primary choice of treatment was percutaneous transluminal
angioplasty (PTA). After an intervention patients continued the same surveillance mode
as before. All thrombotic events and interventions (elective or therapeutic) were record-
ed.
Data analysis
Thrombosis-free survival rates between the subgroups in both groups were tested with
the log rank test. Curves were made with Kaplan-Meier survival analysis showing event-
25
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free graft survival. An event was defined as a thrombotic event without a preceding posi-
tive test, either VP (Group A1, B1 and B2) or Qa (Group A2 and B2). Differences
between incidence rates of thrombosis and of intervention were calculated with Poisson
regression analysis. A P value of less than 0.05 was considered significant.
Power analysis
For calculation of group sizes we made the following assumptions. Our historical throm-
bosis rate was 1.2 event per patient-year [7], but improved after intensifying access sur-
veillance using dynamic VP measurements to approximately 0.85. At that time however,
no specific surveillance protocol was used. We expected the thrombosis rate in the Qa
groups to be lower than in the VP groups based on considerations described in the
Introduction. We calculated that with a follow-up of 100 patient-year a thrombosis rate
difference of 0.25 could be demonstrated (α = 0.05, β = 0.20). Obviously, for differences
greater than 0.25 less follow-up is needed.
Results
Data were evaluated after a follow-up of approximately two times 40 patient-years. An
interim analysis showed that results in VP monitored grafts were much better than antic-
ipated. This justified the conclusion that continuation of the study was not likely to result
in clinically significant differences.
Patient characteristics
Study A included 53 PTFE grafts (51 patients). Twenty-five grafts were monitored by VP
(Group A1) and 28 grafts by Qa measurements (Group A2). Study B included 72 grafts
(68 patients). Thirty-one grafts were assigned to Group B1 (VP) and 41 grafts to Group
B2 (VP + Qa) (Fig. 1).
In study A 19 patients were lost during follow up (8 in Group A1, 11 in Group A2).
Reasons included death or abstinence of dialysis therapy (n = 12), transplantation (n =
3), refusal of further graft monitoring (n = 2), change to peritoneal dialysis (n = 1) or to
another center (n = 1). In study B 15 patients were lost to follow-up (8 in Group B1, 7 in
Group B2). Reasons were death (n = 8), transplantation (n = 4), abstinence of dialysis
therapy (n = 1), and change to peritoneal dialysis (n = 2).
Demographic patient characteristics for both studies are depicted in Table 1. There were
no significant differences in age, percentage diabetics, race, or time on hemodialysis ther-
apy, in either study A or B.
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Outcome
Study A
Total follow up was 37.8 patient-years. Graft monitoring resulted 59 times in positive
tests followed by 55 angiograms, which subsequently resulted in 48 PTA procedures and
7 surgical interventions. Table 2 shows which test(s) led to these interventions. In all
cases of Group A1 it was an increased VP0/MAP, which led to the intervention. In the
vast majority of angiograms venous stenoses were present (Table 3). Graft characteristics
and outcomes of individual patient groups are outlined in Table 4 and 5.
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Table 1. Patient characteristics 
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP + Qa (B2) P
Patients 24 27 NS 31 37 NS
Median age years
(range) 65(26-86) 66(21-84) NS 65(19-80) 61(21-87) NS
Mean age years
(SD) 61 (17) 61 (18) 62 (14) 60 (17)
Gender
male 9 18 0.04 15 16 NS
female 15 9 16 21
Cause of renal failure
diabetes 4 (16%) 7 (26%) NS 8 (26%) 4 (11%) NS
hypertension 8 8 2 2
glomerulonephritis 3 2 3 2
polycystic kidney 
disease 3 0 0 5
other 4 7 13 19
unknown 2 3 5 5
Race
Caucasian 18 (75%) 23 (85%) NS 30 (97%) 30 (81%) NS
black 5 4 0 4
Asian 1 0 1 3
Median HD 18.1 13.9 NS 22.0 24.8 NS
therapy months
(range) (2.3-88.8) (0.9-116.7) (0.0-281.0) (0.2-302.1)
Mean HD therapy 27.9 (26.9) 22.6 (28.2) 43.9 (58.2) 44.3 (69.6)
months (SD)
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During the follow-up, 12 thrombotic events occurred (6 in each patient group), resulting
in a thrombosis frequency of 0.31 per patient-year. In both subgroups thrombosis was
predicted by a positive test (VP or Qa) in 2 occasions, but thrombosis occurred pending
the angiography (2 - 15 days after obtaining positive tests). In 8 grafts thrombosis was
not preceded by an abnormal VP or flow, which resulted in an unpredicted thrombosis
rate of 0.19 and 0.24 per patient-year (P = NS). No anatomical information is available
from these 8 grafts with thrombosis. Reasons included: no attempt to reestablish patency
or surgical thrombectomy without intra-operative angiography.
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Table 3. Localization of stenotic lesions in grafts of patients referred for PTA
Study A Study B
VP (A1) Qa (A2) VP(B1) VP + Qa (B2)
Localization
Venous graft +/- outflowa 24 (92%) 19 (86%) 22 (96%) 20 (77%)
Arterial graftb 0 (0%) 1 (5%) 0 (0%) 1 (4%)
Venous + arterial graftc 2 (8%) 2 (9%) 1 (4%) 5 (19%)
Total PTA 26 22 23 26
a stenosis at or near the venous anastomosis and/or in the venous outflow tract
b stenosis at or near the arterial anastomosis
c combination of a and b, i.e. a stenosis at or near the venous anastomosis and/or in the venous outflow tract and a stenosis at
or near the arterial anastomosis
Table 2. Which positive test led to intervention?
Study A Study B
VP (A1) Qa (A2) VP (B1) VP + Qa (B2)
VP0/MAP 15 - 12 6
VP200 0 - 4 0
VP0/MAP + VP200a 15 - 9 8
Qa - 25 - 3
Qa +VPb - - - 13
Total (PTA) 30 (26) 25 (22) 25 (23) 30 (26)
a both tests were positive
b VP means either a positive VP0/MAP, or a positive VP200, or both
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Kaplan-Meier survival curves did not show a significant difference between the sub-
groups (Table 5, Fig. 2). The 6 months event-free survival (an event equals thrombosis
not predicted by the test) was 87% for the VP group, and 84% for the Qa group (P = NS).
Study B
The total follow up period was 42.7 patient-years. Graft monitoring resulted 72 times in
positive tests followed by 55 angiograms, which subsequently resulted in 49 PTA proce-
dures and 6 surgical interventions. Table 2 shows which positive test(s) led to an inter-
vention. In 90% of cases there was an elevated VP0/MAP. Venous stenosis (at or near the
venous anastomosis or in the venous outflow tract) was present in 98% of the grafts
treated with PTA (see Table 3). Graft characteristics and outcomes of individual patient
groups are outlined in Table 4 and 5.
Thirty thrombotic events occurred (12 in the VP group, 18 in the VP + Qa group), that is
0.7 per patient-year. Five out of the 12 thrombosis in the Group B1 were preceded by a
positive test, but thrombosis occurred after 2 - 15 days pending the angiography. In all
five cases thrombectomy was done and a venous stenosis was found. In Group B2, 12 out
of 18 thromboses were predicted by one or more positive tests. In 7 cases thrombosis
occurred after 3 - 20 days pending the angiography (all of these seven grafts showed a
venous stenosis after thrombectomy), and in 5 cases intervention was not done for vari-
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Figure 2. Study A. Graft survival with non-predicted thrombosis
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ous reasons, including graft infection, poor clinical condition and switch to peritoneal
dialysis. In 13 cases thrombosis was not preceded by a positive test, resulting in a throm-
bosis frequency of 0.32 (Group B1) and 0.28 (Group B2) (P = NS). Ten of these 13
thromboses were treated by radiological thrombolysis. Stenoses were found at the venous
anastomosis (n = 5, Group B1; n = 3, Group B2), at the arterial anastomosis (n = 1,
Group B2), or at both anastomoses (n = 1, Group B2). In 3 grafts it was impossible to
obtain anatomical information, because no attempt was made to reestablish patency.
Kaplan-Meier survival curves did not show a significant difference between the sub-
groups (Table 5, Fig. 3). The 6 months event-free survival (an event equals thrombosis




Table 4. Graft characteristics
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP + Qa (B2) P
Grafts 25 28 31 41
Median age graft 6.7 4.6 11.6 6.0
months (range) (1.0-49.7) (1.2-28.4) NS (0.0-73.6) (0.0-100.0) NS
Mean age graft 12.8 8.3 18.1 16.4
months (SD) (13.8) (7.6) (20.9) (24.8)
Configuration graft
looped, forearm 23 26 NS 31 37 NS
straight, upperarm 2 2 0 4
Anticoagulant therapy
acenocoumerol 14 15 20 23
aspirin 5 2 3 5
combination 1 0 2 0
none 5 11 6 13
Follow-up
patient-years 21.3 16.5 21.6 21.1
median months 11.2 5.8 5.9 5.1
(range) (0.9-15.5) (1.1-15.2) 0.016 (1.7-20.4) (0.4-20.4) NS
mean months 10.4 7.2 8.4 6.2
(SD) (4.4) (4.9) (5.7) (4.9)




Study A Study B
VP (A1) Qa (A2) P VP (B1) VP + Qa (B2) P
Interventions/ pt.-yr.
(n pts) 1.41 (17) 1.52 (11) 1.16 (16) 1.42 (20)
balloon angioplasty 
(n) 26 22 23 26
surgical (n) 4 3 2 4
Thromboses total 
(n pts) 6(4) 6(4) 12(10) 18(16)
predicted / 
unpredicted 2/4 2/4 5/7 12/6
Unpredicted 
thromboses/ pt.-yr. 0.19 0.24 NS 0.32 0.28 NS
6 mnth. event-freea
surv. rate (%) 87 84 NS 85 88 NS
12 mnth. event-freea
surv. rate (%) 77 84 NS 85 80 NS
a an event is defined as an unpredicted thrombosis
Figure 3. Study B. Graft survival with non-predicted thrombosis
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Discussion
This randomized, prospective multi-center trial allows a number of important conclu-
sions. Firstly, we confirm that thrombosis rates in patients monitored and selected for
corrective interventions based on VP or Qa can be maintained below the quality of care
standards formulated by the NKF-DOQI committee [4]. Secondly, we show that throm-
bosis rates in groups monitored by VP or Qa alone or by the combination of tests do not
differ. Thirdly, only a small minority of patients was selected for corrective interventions
by Qa alone in the group with combined monitoring of VP and Qa. Fourthly, after
obtaining abnormal tests subsequent diagnostic and interventional procedures should be
instituted on short notice. It seems likely that the number of thromboses during the
waiting time can be reduced. Finally, we confirm that static VP is more effective than
dynamic VP for monitoring dialysis grafts.
The present study confirms the usefulness of VP and Qa measurements as access surveil-
lance variables. Previously, we have presented the theoretical basis for the assumption
that Qa measurements are better than VP (i.e. dynamic) measurements as a monitoring
tool (summarized in [26]). This is based on the fact that some stenoses are located in the
arterial flow tract that is upstream of the venous needle. These lesions increase resistance
and reduce Qa without increasing VP, possibly even decreasing VP. Several studies have
indicated that arterial stenoses occur in up to 29% of thrombosis cases [20-23]. In the
present study, we found a strong predominance of venous lesions in the patients referred
for angiography. In some patients having a graft thrombosis without a preceding positive
test, thrombectomy was done. Also, in those patients venous lesions were more likely
than arterial lesions.
Qa measurements have already been recognized as the preferred monitoring tool for vas-
cular access surveillance [4,27]. However, these recommendations are primarily based on
clinical studies with a non-randomized or observational setup [19,25,28-30]. To our
knowledge, only one study compared Qa with static VP as surveillance variable. Sands et
al. [8] showed that intervention based on monthly Qa measurement or on monthly static
VP measurements reduced thrombosis rates in comparison with non-monitored con-
trols. Some important differences between the two studies exist. The present study also
includes a program combining VP and Qa. Theoretically, this combination is likely to be
the most effective program [18]. Furthermore, the study population of Sands et al. con-
sisted predominantly of AV fistulae (almost two-third in the control and monitored
groups) which are less likely to clot. Also, threshold for referral for angiogram (750
mL/min vs. 600 mL/min in our Qa groups), and frequency of measurements (monthly
VP vs. weekly in our VP groups) differed. There is some controversy about the optimal
frequency. Some advocate the use of dynamic pressures weekly and static VP every two
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weeks [4], others suggest to measure dynamic VP every dialysis [27], or static VP every
week [31]. In the present study, we measured both dynamic and static VP once weekly
during the same dialysis session. Our results indicate that graft surveillance using VP or
Qa measurements strictly organized as in the present study results in identical thrombo-
sis rates. This does not exclude the possibility that in patients who develop more arterial
lesions for whatever reason, surveillance using Qa would result in lower thrombosis rates
than using VP measurements.
In our study most referrals for intervention in patients monitored by VP measurements
alone (Group A1 and B1) were based on static VP measurements. Although dynamic VP
was successfully used as part of an access surveillance program in some studies
[6,11,16,32], there is convincing evidence that dynamic VP does not accurately reflect
true intra-access pressure, and therefore, does not reflect resistance caused by stenosis
formation [14]. Dynamic VP is highly biased by pump flow, blood tubing, needle size,
and blood pressure [33]. Static VP measurements, on the other hand, particularly when
corrected for mean arterial pressure, avoid these potential confounders.
Also in Group B2 (combination of VP and Qa measurements) most referrals were based
on VP and only 3 out of 30 referrals were based on Qa alone. These data indicate that
when VP measurements are well organized, adding periodic Qa measurements is of lim-
ited value (Group B1 versus B2). On the other hand, study A clearly shows that when no
VP measurements are done periodic Qa measurements result in identical thrombosis
rates, proving the effectiveness of Qa as surveillance variable.
In this study 21 of the 42 thromboses occurred despite preceding positive tests. Sixteen
thromboses occurred 2 to 20 days after obtaining the abnormal tests pending further
diagnostic and correctional interventions. These results further support the idea that an
increased VP and/or low Qa indeed predict imminent thrombosis. It seems likely that
immediate institution of further treatment could have decreased the number of throm-
boses.
The 21 thromboses, which were not preceded by positive tests, should not all be consid-
ered as failures of the tests. Flow is directly related to blood pressure. Blood pressure may
show considerable variability in hemodialysis patients and is likely to reach its lowest lev-
els in the first hours after the hemodialysis session and especially during the night [34].
Therefore, it is possible that flow is adequate at the time measurements are done, but
reaches levels associated with thrombosis in the interdialytic period.
Several issues need to be addressed with respect to the present study.
Firstly, our power calculations were based on the assumption that there would be a dif-
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ference in thrombosis rates between VP and Qa monitored patients. However, the strict
adherence to the surveillance protocols improved our results using VP measurements
when compared to our historic controls. Differences in the present study were not statis-
tically significant. The results indicated that continuation of the study was not likely to
result in clinically relevant differences.
Secondly, we measured Qa every two months, but repeated the measurement after one
month if Qa reached levels between 600 and 800 mL/min. This frequency was mainly
based on feasibility considerations. It remains unclear, whether a higher frequency of Qa
measurements, as was suggested by others [8,27] would decrease the already low throm-
bosis rate further. Furthermore, we can not exclude the possibility that decreasing the
frequency of VP measurements, for instance every 2 weeks, as was suggested elsewhere
[4], would result in identical results.
Additionally, threshold levels for selection for referral may vary. We used a level of 600
mL/min as Qa threshold level for referral. We based our choice on earlier results [35] and
the NKF-DOQI considerations [4]. Others have chosen 650 or 750 mL/min [8,27]. This
may affect outcome. A recent meta-analysis by Paulson et al. [36] concluded that a single
Qa measurement did not appear to have enough accuracy to be a clinically useful predic-
tor of graft thrombosis or failure. Furthermore, it has been suggested that a decrease in
Qa over time of > 15% is particularly predictive of impending graft failure [29]. The
present study was not specifically designed to study that issue. However, in the patients
who were monitored by Qa measurements (Group A2 and B2) none of the unpredicted
thromboses were preceded by a decrease in Qa of more than 15%. As a consequence,
none of these thromboses would have been predicted by this criterion. Furthermore, in
the patients who did not reach the threshold levels of the present study but did show a
decrease in Qa of more than 15% (n = 11 (A2), n = 8 (B2); average decrease: 1090
mL/min to 740 mL/min) none experienced thrombosis. So, our data do not support the
hypothesis that a decrease in Qa of > 15% as selection parameter would confer any bene-
fit when added to either of the Qa protocols. Also, a recent study showed that a decrease
in Qa over time had little predictive value [37].
In unmonitored PTFE grafts the total graft access event rate related to thrombosis or
stenosis was 1.51 per patient-year [7] of which 1.24 event per patient-year (82%) was
caused by thrombosis. In the present studies the total graft event rate (related to throm-
bosis and stenosis) was 1.88 (range 1.69-2.27). On average, all thrombotic episodes
accounted for 0.52 event per patient-year (28%) and the unpredicted thromboses
accounted for 0.26 event per patient-year (14%). So, the introduction of a well structured
surveillance program resulted in a substantial decrease in interventions for treatment of
thrombosis at the expense of an increase of the number of elective interventions, mainly
PTA. Our study was not designed as a cost effectiveness analysis. It seems likely, however,
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that this shift in type of interventions is associated with a decrease in access related mor-
bidity and mortality.
What may be the implications of the present study for everyday clinical practice? We
showed that using the surveillance protocol of this study outcome with respect to throm-
bosis rate is equal in Qa monitored grafts and in VP monitored grafts and that there is no
rationale in combining the two methods. It is important to note that our population
contained fewer diabetics than the average US dialysis population. It is possible that this
affects outcome, since inflow stenosis (which will not be detected by VP measurements)
may occur more frequently in diabetics. Each dialysis center should decide which
method is best suitable for their dialysis practice. VP measurements are easy to obtain
and require little time investment. However, they need discipline. Qa measurements are
more time consuming and a special device is needed. We showed that by measuring Qa
every 4 to 8 weeks identical results can be obtained as with weekly VP assessments. The
decision which method to use, will be primarily based on the preferences of those
involved in the access care and on the possibilities to implement a certain surveillance
strategy.
In conclusion, our studies show that standardized monitoring of VP or Qa or the combi-
nation of both and subsequent corrective intervention can decrease thrombosis rates to
below 0.5 per patient-year, which is recommended by the Vascular Access Task Force of
the NKF-DOQI Committee as quality of care standard [4]. When applying the present
protocol, VP, Qa, or the combination as variables for selection of patients for corrective
intervention are equally effective in reducing thrombosis rates in hemodialysis access
grafts.
Acknowledgements
Presented at the 32nd Annual Meeting of the American Society of Nephrology, Miami
Beach, Florida, USA, November 5-8, 1999. The authors would like to acknowledge the
following contributors: Adri Diepenbroek, Eemland Hospital, Amersfoort; Carry M. van
der Beek, Monique M. Harskamp, Eddy van der Weele, Gelderse Vallei, Wageningen;




hoofdstuk 03  09-10-2001  10:04  Pagina 35
References
1. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc
Nephrol 7: 523-535, 1996
2. USRDS. The economic cost of ESRD, vascular access procedures, and Medicare spending for
alternative modalities of treatment. United States Renal Data System: Am J Kidney Dis 30
(Suppl 1): S160-S177, 1997
3. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascu-
lar access morbidity in the United States. Kidney Int 43: 1091-1096, 1993
4. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation: Am J
Kidney Dis 30 (Suppl 3): S152-S191, 1997
5. Beathard GA: Thrombolysis for the treatment of thrombosed dialysis access grafts: a nephrol-
ogist’s view. Semin Dial 8: 162-165, 1995
6. Cayco AV, Abu-Alfa AK, Mahnensmith RL, Perazella MA: Reduction in arteriovenous graft
impairment: results of a vascular access surveillance protocol. Am J Kidney Dis 32: 302-308,
1998
7. Bosman PJ, Blankestijn PJ, van der Graaf Y, Heintjes RJ, Koomans HA, Eikelboom BC: A com-
parison between PTFE and denatured homologous vein grafts for haemodialysis access: a
prospective randomised multicentre trial. The SMASH Study Group. Eur J Vasc Endovasc Surg
16: 126-132, 1998
8. Sands JJ, Jabyac PA, Miranda CL, Kapsick BJ: Intervention based on monthly monitoring
decreases hemodialysis access thrombosis. ASAIO J 45: 147-150, 1999
9. Bassiouny HS, White S, Glagov S, Choi E, Giddens DP, Zarins CK: Anastomotic intimal hyper-
plasia: mechanical injury or flow induced. J Vasc Surg 15: 708-716, 1992
10. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D: Dialysis access grafts:
anatomic location of venous stenosis and results of angioplasty. Radiology 195: 135-139, 1995
11. Roberts AB, Kahn MB, Bradford S, Lee J, Ahmed Z, Fitzsimmons J, Ball D: Graft surveillance
and angioplasty prolongs dialysis graft patency. J Am Coll Surg 183: 486-492, 1996
12. Safa AA, Valji K, Roberts AC, Ziegler TW, Hye RJ, Oglevie SB: Detection and treatment of dys-
functional hemodialysis access grafts: effect of a surveillance program on graft patency and
the incidence of thrombosis. Radiology 199: 653-657, 1996
13. Smits HF, Van Rijk PP, Van Isselt JW, Mali WP, Koomans HA, Blankestijn PJ: Pulmonary
embolism after thrombolysis of hemodialysis grafts. J Am Soc Nephrol 8: 1458-1461, 1997
14. Besarab A, Sullivan KL, Ross RP, Moritz MJ: Utility of intra-access pressure monitoring in
detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 47: 1364-
1373, 1995
15. Beathard GA: Percutaneous transvenous angioplasty in the treatment of vascular access steno-
sis. Kidney Int 42: 1390-1397, 1992
36
Chapter 3
hoofdstuk 03  09-10-2001  10:04  Pagina 36
16. Schwab SJ, Raymond JR, Saeed M, Newman GE, Dennis PA, Bollinger RR: Prevention of
hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int 36: 707-711,
1989
17. Sands JJ, Miranda CL: Prolongation of hemodialysis access survival with elective revision. Clin
Nephrol 44: 329-333, 1995
18. Smits JHM, Blankestijn PJ: Haemodialysis access: the case for prospective monitoring. Curr
Opin Nephrol Hypertens 8: 685-690, 1999
19. Bosman PJ, Boereboom FT, Smits HF, Eikelboom BC, Koomans HA, Blankestijn PJ: Pressure
or flow recordings for the surveillance of hemodialysis grafts. Kidney Int 52: 1084-1088, 1997
20. Beathard GA: Mechanical versus pharmacomechanical thrombolysis for the treatment of
thrombosed dialysis access grafts. Kidney Int 45: 1401-1406, 1994
21. Roberts AC, Valji K, Bookstein JJ, Hye RJ: Pulse-spray pharmacomechanical thrombolysis for
treatment of thrombosed dialysis access grafts. Am J Surg 166: 221-225, 1993
22. Valji K, Bookstein JJ, Roberts AC, Oglevie SB, Pittman C, O’Neill MP: Pulse-spray pharmaco-
mechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and
comparison of original and current techniques. Am J Roentgenol 164: 1495-1500, 1995
23. Swan TL, Smyth SH, Ruffenach SJ, Berman SS, Pond GD: Pulmonary embolism following
hemodialysis access thrombolysis/thrombectomy. J Vasc Interv Radiol 6: 683-686, 1995
24. Krivitski NM: Theory and validation of access flow measurement by dilution technique dur-
ing hemodialysis. Kidney Int 48: 244-250, 1995
25. Bosman PJ, Boereboom FT, Bakker CJ, Mali WP, Eikelboom BC, Blankestijn PJ, Koomans HA:
Access flow measurements in hemodialysis patients: in vivo validation of an ultrasound dilu-
tion technique. J Am Soc Nephrol 7: 966-969, 1996
26. Blankestijn PJ, Smits JH: How to identify the haemodialysis access at risk of thrombosis? Are
flow measurements the answer? Nephrol Dial Transplant 14: 1068-1071, 1999
27. Jindal KK, Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A: Clinical prac-
tice guidelines for vascular access. J Am Soc Nephrol 10 (Suppl 13): S297-S305, 1999
28. May RE, Himmelfarb J, Yenicesu M, Knights S, Ikizler TA, Schulman G, Hernanz Schulman
M, Shyr Y, Hakim RM: Predictive measures of vascular access thrombosis: a prospective study.
Kidney Int 52: 1656-1662, 1997
29. Neyra NR, Ikizler TA, May RE, Himmelfarb J, Schulman G, Shyr Y, Hakim RM: Change in
access blood flow over time predicts vascular access thrombosis. Kidney Int 54: 1714-1719,
1998
30. Wang E, Schneditz D, Nepomuceno C, Lavarias V, Martin K, Morris AT, Levin NW: Predictive
value of access blood flow in detecting access thrombosis. ASAIO J 44: M555-M558, 1998
31. Besarab A, Frinak S, Sherman RA, Goldman J, Dumler F, Devita MV, Kapoian T, Al-Saghir F,




hoofdstuk 03  09-10-2001  10:04  Pagina 37
32. Allon M, Bailey R, Ballard R, Deierhoi MH, Hamrick K, Oser R, Rhynes VK, Robbin ML,
Saddekni S, Zeigler ST: A multidisciplinary approach to hemodialysis access: prospective eval-
uation. Kidney Int 53: 473-479, 1998
33. Besarab A, Dorrell S, Moritz M, Michael H, Sullivan K: Determinants of measured dialysis
venous pressure and its relationship to true intra-access venous pressure. ASAIO Trans 37:
M270-M271, 1991
34. Luik AJ, Struijk DG, Gladziwa U, von Olden RW, von Hooff JP, de Leeuw PW, Leunissen KM:
Diurnal blood-pressure variations in haemodialysis and CAPD patients. Nephrol Dial
Transplant 9: 1616-1621, 1994
35. Bosman PJ, Boereboom FTJ, Eikelboom BC, Koomans HA, Blankestijn PJ: Graft flow as a pre-
dictor of thrombosis in hemodialysis grafts. Kidney Int 54: 1726-1730, 1998
36. Paulson WD, Ram SJ, Birk CG, Work J: Does blood flow accurately predict thrombosis or fail-
ure of hemodialysis synthetic grafts? A meta-analysis. Am J Kidney Dis 34: 478-485, 1999
37. Paulson WD, Ram SJ, Birk CG, Zapczynski M, Martin SR, Work J: Accuracy of decrease in
blood flow in predicting hemodialysis graft thrombosis. Am J Kidney Dis 35: 1089-1095, 2000
38
Chapter 3
hoofdstuk 03  09-10-2001  10:04  Pagina 38
Hemodialysis access imaging: comparison of flow-
interrupted contrast-enhanced MR angiography and
digital subtraction angiography
Johannes H.M. Smits1, Clemens Bos2, Otto E.H. Elgersma2,
Wil A.M.A. van der Mark1, Peter J. Blankestijn1, Chris J.G. Bakker2,
Jan J. Zijlstra2, Willem P.Th.M. Mali2
1 Department of Nephrology, University Medical Center, Utrecht
2 Department of Radiology, University Medical Center, Utrecht
Chapter 4
hoofdstuk 04  09-10-2001  10:04  Pagina 39
Abstract
Background. To compare flow-interrupted contrast-enhanced magnetic resonance
angiography (CE-MRA) in hemodialysis access imaging with conventional digital sub-
traction angiography (DSA).
Methods. Twenty-two accesses (14 AVG, 8 AVF) in eighteen patients were imaged with
flow-interrupted CE-MRA and subsequent conventional DSA. Anastomotic diameters in
AVG and post-anastomotic diameter in AVF were measured and set out against an adja-
cent normal segment. Lumen reduction at MRA and DSA was assessed independently by
two radiologists. Lumen reductions were compared with Pearson correlation. Inter-
observer agreement was analyzed with Kappa (κ) statistics.
Results. Image quality obtained with flow-interrupted CE-MRA was considered excellent
in 77%, and good in 23%. Pearson correlation coefficient between MRA and DSA was
0.79 (Obs. 1) and 0.82 (Obs. 2) (P < 0.0001). Inter-observer agreement showed a κ of
0.67 for MRA and 0.93 for DSA. MRA lumen reductions were on average slightly higher
than DSA scores by both observers (3.7% and 5.7%).
Conclusion. Flow-interrupted CE-MRA is capable of adequate hemodialysis vascular
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Introduction
Thrombosis remains the most important complication in hemodialysis arteriovenous
fistulae (AVF) and grafts (AVG) with an incidence of 0.5 - 2.5 per patient-year [1-6].
Stenosis due to progressive intimal hyperplasia is associated with vascular access throm-
bosis [7-11]. Several surveillance tools have been introduced that offer the ability to iden-
tify vascular accesses at risk of thrombosis [1,12,13]. To treat a failing access (either by
percutaneous transluminal angioplasty (PTA) or by surgical intervention [1]), it is neces-
sary to identify the underlying problem, i.e. in most cases one or more stenoses, predom-
inantly found at the anastomosis of an AVF and at the venous anastomosis of an AVG
[7-11]. The conventional technique to identify and locate stenosis has predominantly
been digital subtraction angiography (DSA). However, there are several drawbacks: the
radiation load for the patient and radiology personnel, the use of potentially nephrotoxic
iodinated contrast agents, and limited spatial information [14]. Magnetic resonance
angiography (MRA) does not have these disadvantages and could offer an attractive
alternative. In addition, MRA offers the possibility to measure access flow. Access flow
has been shown to be a better parameter for impending vascular access failure than
anatomical information alone [6,12,15].
However, a major problem with flow-based approaches to MRA, such as phase-contrast
(PC) and time-of-flight (TOF), has always been the frequent occurrence of flow artifacts
41
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Figure 1. Evolution in MRA of the hemodialysis access: A.) time-of-flight MRA, B.) phase-contrast MRA, C.) flow-
interrupted contrast-enhanced MRA
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in regions with disturbed flow that complicate interpretation of the MR angiograms.
Especially near stenoses (but also near bends and cusps [16]), the appearance of the
lumen is distorted by a combination of dephasing, displacement and, for TOF methods,
saturation artifacts [17]. Application of PC and TOF to hemodialysis accesses, i.e. both
AVF and AVG, also suffers from the above types of inaccuracies [18,19], but interpreta-
tion of the angiograms is further complicated by the large range of flow rates that occurs
in these vessels: roughly 100 - 3000 ml/min. As flow disturbances tend to increase with
flow rate, signal voids may easily arise at mild narrowings or sharp-angled anastomoses,
when a high flow rate is present [20].
Contrast-enhanced (CE) MR angiography is less sensitive to these artifacts [21], and has
been reported to improve hemodialysis access visualization, when compared to TOF and
PC [22]. However, flow related artifacts remain present under the extreme flow condi-
tions that occur in hemodialysis accesses [23]. To eliminate these artifacts, we borrow
from the procedure used for DSA of the hemodialysis access, and use a cuff to obstruct
the blood flow temporarily (Figure 1) [24,25]. We recently described the technical details
of this flow-interrupted CE-MRA imaging technique [23].
This study was designed to validate our MRA technique anatomically, and for this pur-
pose we compared anastomotic (AVG) and post-anastomotic diameters (AVF) of MRA
images obtained with flow-interruption and selective contrast administration with those
diameters scored on conventional DSA imaging of hemodialysis accesses.
Patients and methods
Between March 2000 and March 2001 18 hemodialysis patients with functioning vascular
accesses were included. Twenty-two MRA/DSA series were made in these patients. Eleven
patients (3 M, 8 F) had an AVG. A total of 14 MRA/DSA series were made in these
patients. Seven patients had an AVF (all male), with eight MRA/DSA series. Mean age for
the AVG patients was 56.1 ± 16.3 years, and 59.9 ± 16.9 for the AVF patients. The study
was approved by our institutional ethical review board. Informed consent was obtained
from all patients. All patients underwent MR angiography including MR flow measure-
ment and subsequent DSA on the same day.
Imaging Techniques
MRA
All examinations were performed on a 1.5-T clinical scanner (Gyroscan ACS-NT, Philips
Medical Systems, Best, The Netherlands). Patients were imaged in supine position, enter-
ing the scanner feet-first to facilitate communication with the physician at the front of
the scanner. A 17-gauge plastic needle (Clampcath, Medikit Co., Tokyo) was inserted in
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the hemodialysis access and fixed with tape. Two luerlock syringes, 20 or 30 ml each, con-
taining twentyfold diluted Gd-DTPA (Magnevist, Schering, Berlin, Germany) in saline
were connected to the needle via 100-cm luerlock tubing. An MR-compatible cuff was
wrapped around the upper arm and fixed with a strap. A rectangular surface coil of 10 ×
40 cm was positioned on the forearm of the patient for signal reception.
First, three orthogonal two-dimensional (2D) phase-contrast surveys were obtained.
Filling of the access with contrast was monitored using a fast 2D spoiled gradient echo
sequence with complex mask subtraction, providing one image every 0.9 seconds. Care
was taken to select an imaging plane showing the arterial and venous limbs of the access
well separated.
The images were reconstructed immediately and were presented to the radiologist on an
LCD-screen in the scanner room. A 3D image of the access was acquired using a spoiled
gradient echo with centric k-space order. Scan parameters included: repetition time 6.1
msec, echo time 1.8 msec, excitation angle 45º, field-of-view 400 × 100 mm, acquisition
matrix 512 × 100. The volume consisted of 64 1.0-mm partitions that were zero-filled
and reconstructed every 0.5 mm. The volume had a sagittal orientation to prevent over-
lap from the trunk. More slices were added if necessary to cover the left-right extent of
the access. Scan time was 38 to 48 seconds.
We first reduced access flow by inflating the cuff to diastolic blood pressure. Then, con-
trast was hand-injected until the access downstream of the puncture site was adequately
filled. Next, the flow in the access was blocked, by increasing the cuff pressure to well
above the systolic pressure, enabling retrograde filling of the upstream part of the access,
the arterial anastomosis and the native artery. When the filling of the access was sufficient
and stable on the complex subtraction images, we proceeded to the 3D acquisition. After
completion of the acquisition, the cuff was released.
DSA
DSA was performed on dedicated angiography equipment (DVI-s and Integris 3000,
Philips Medical Systems, Best, The Netherlands). The DSA studies were performed by
experienced radiologists who were aware of the clinical information regarding vascular
access function and with access to previously performed DSA studies. Our standard DSA
imaging strategy comprises of at least four DSA series in fistulae and five in grafts. One
series was made to visualize the loop of the graft. The second series visualized the arterial
anastomosis by injecting iodinated contrast agent (Ultravist, Schering, Berlin, Germany)
into the arterial limb of the graft during upper arm cuff compression of about 200
mmHg. This ensured adequate filling of the arterial anastomosis. Then the venous anas-
tomosis and part of the upper arm veins were visualized. A further two series were per-
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formed to visualize the veins up to the superior caval vein. In case of overprojection of
the anastomoses, additional projections of the anastomotic areas were made.
Image Analysis
Image quality was assessed on the scale of excellent, good, or non-diagnostic. Both the
DSA and MRA multi-planar reformat (MPR) images were blindly reviewed by two expe-
rienced vascular radiologists independently. For the DSA, all lumen diameters were
measured on the hard-copies with a mechanical caliper with a digital display (PAV
Electronics, Vaduz, Liechtenstein). For MRA, the data were presented on a console
(EasyVision, Philips Medical Systems, Best, The Netherlands). The lumen diameters were
measured from vessel cross-sections that were created by multi-planar reformatting of
the volume data perpendicular to the vessel axis.
For comparison, we took the vascular access segments that were easily definable and were
responsible for most clinical problems. For AVF, we only scored the narrowest diameter
near the anastomosis (within three centimeter) and compared it with the diameter of a
normal segment of the vein downstream. This resulted in one ratio number for the AVF,
from which the relative degree of stenosis was calculated.
For AVG, the narrowest diameter of the arterial anastomosis was divided by a normal
arterial graft segment nearby the anastomosis, and the narrowest segment of the venous
anastomosis was divided by a close-by normal segment of the graft. Therefore, two ratio
measurements were done per AVG per observer per imaging method. The degree of
stenosis was calculated from these ratios.
Statistical analysis
Correlations between the imaging methods were assessed with calculation of the Pearson
correlation coefficients (r). Furthermore, findings were categorized in the following
lumen reduction percentages: 0% - 49%, 50% - 74%, and 75% - 99%, and 100%. Kappa
(κ) coefficients were calculated based on these categories. Inter-observer variation was
measured for MRA and DSA. A P value < 0.05 was considered statistically significant.
Results
Twenty-two vascular accesses in 18 patients were depicted with conventional DSA and
contrast-enhanced flow-interrupted MR angiography. In one case, patient movement
during the scan resulted in non-diagnostic image quality of the MRA image. Five of the
MRA series were considered of good diagnostic quality, and 16 were considered to be of
excellent quality for diameter assessment. Therefore, 21 MRA series remained for com-
parison. For AVF, seven lumen reductions were measured for each imaging method per
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Figure 2. Contrast-enhanced MRA and DSA of an AV graft. Coronal maximum intensity projection provides an
overview of the graft (a). Oblique maximum intensity projection of the CE-MRA data set (b) and conventional
angiogram (c) demonstrate a stenosis at the venous anastomosis (straight arrows). At the arterial anastomosis
(curved arrows), oblique maximum intensity projection of the CE-MRA data set (d) and conventional angiogram
(e) show a mild stenosis. In addition, CE-MRA clearly delineates the narrowing of the venous limb of the graft, the
puncture aneurysm at the arterial limb, and the dilated native veins downstream of the anastomosis.
Figure 3. Contrast-enhanced MRA and DSA of a AV Brescia-Cimino fistula. Coronal maximum intensity projection
provides an overview of the fistula (a). Oblique coronal view of the CE-MRA data (b) with corresponding conven-
tional angiogram (c), and oblique saggital view of the CE-MRA data (d) with corresponding conventional
angiogram (e). The images clearly show the native artery (straight arrows), the side-to-side anastomosis and the
stenoses in the venous part of the access (curved arrows).
a edcb
a edcb
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Figure 4. Scatter plots show measurements of maximum stenosis percentage obtained at MRA versus those obtained
at conventional DSA by observer 1 (r = 0.79) and observer 2 (r = 0.82)
Figure 5. Example of the CE-MRA of an outflow tract up to the superior vena cava
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observer. In AVG, MRA stenotic ratios could be calculated in 21 segments (28 expected):
seven could not be measured because of the following reasons: 3 venous anastomoses
were extended to the axilla and were therefore not imaged, 3 arterial anastomoses were
not depicted because fill-up was not complete, and one venous anastomosis was com-
pressed under the cuff during MRA examination. DSA stenotic ratios could be calculated
in 24 segments (28 expected); four ratios could not be calculated because the AV grafts
were extended to more proximal veins and these segments were not adequately depicted.
Access flow measured with MRA was 890 ± 449 mL/min in AVG, and 677 ± 384 mL/min
in AVF. Examples of the image quality are given in Figure 2 and 3 for AVG and AVF
respectively.
Pearson analysis of the MRA data sets with the corresponding DSA data sets revealed a
significant correlation between both methods by both observers (Figure 4, r = 0.79 and r
= 0.82 respectively, both P ≤ 0.0001). The observers measured on average more severe
lumen reductions at the MRA when compared to DSA: +3.7% (2.8% SEM) for observer
1, and +5.7% (2.6% SEM) for observer 2. Categorical scores are shown in Table 1. Inter-
observer categorical analysis revealed a κ of 0.67 for MRA and 0.93 for DSA.
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Table 1. Inter-observer agreement shown as categorized lumen reduction measurements
of maximum stenosis scores at MRA (κ = 0.67) versus DSA (κ = 0.93) 
MRA Obs. 2
MRA Obs. 1 0% - 49% 50% - 74% 75% - 99% 100% Total
0% - 49% 11 1 0 0 12
50% - 74% 4 11 0 0 15
75% - 99% 0 0 0 0 0
100% 0 0 0 1 1
Total 15 12 0 1 28
DSA Obs. 2
DSA Obs. 1 0% - 49% 50% - 74% 75% - 99% 100% Total
0% - 49% 21 0 0 0 21
50% - 74% 1 9 0 0 10
75% -99% 0 0 0 0 0
100% 0 0 0 0 0
Total 22 9 0 0 31
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Discussion
This study shows that a selective MR angiography technique is able to deliver high quali-
ty visualization of hemodialysis AVG and AVF. Flow artifacts are eliminated by temporar-
ily interrupting the blood flow, as is common practice in DSA examinations of
hemodialysis accesses [25]. Up to now, flow artifacts have seriously hampered MRA of
AVG and AVF [18,20], since the large variation of flow rates in these vessels, between
patients but also in the course of time, made it hard to assess whether a signal narrowing
was realistic or flow related.
Compared to DSA, flow-interrupted contrast-enhanced MRA shows an excellent correla-
tion when the most problematic areas (i.e. the anastomoses) are evaluated. This finding
was expected, since both imaging methods fill-up the lumen of the graft with contrast-
agents. In some early experiments with this new technique, we found contrast layering
along the vessel wall. After adjusting the technique by injecting the contrast solution
more rapidly, this artifact disappeared. Also, the time required for an entire MRA
sequence decreased from about 40 minutes in the early cases of this study to 30 minutes
after obtaining more experience. This difference in duration can be explained by
improvements in planning of the sequence.
Previous studies that compared non-contrast-enhanced MRA in vascular accesses
[18,19] or contrast-enhanced non-flow interrupted MRA in other vascular beds [26]
showed an overestimation of stenosis assessment. In this study a slightly higher degree of
stenosis (maximally about 5.7%) by MRA when compared to DSA still exists. Possibly,
DSA underestimates lumen reduction, which is conceivable, since the percentage stenosis
can only be assessed by DSA in one or two directions. Another explanation for this phe-
nomenon could be that MRA overestimates the real stenosis because of the limited spa-
tial resolution [27]. However, the differences between both techniques were minimal and
for clinical stenosis assessment both techniques suffice.
This study further shows that direct injection strongly reduces the required contrast
dose, and thus offers the possibility to repeat the exam without the need for large con-
trast dosages. The issue of synchronizing acquisition and peak contrast concentration,
which is a problem of intravenously injected 3D CE-MRA, is circumvented.
MRA has a number of benefits with respect to DSA, the present method of choice for
anatomic hemodialysis access evaluation. The images acquired are three-dimensional
and can be reformatted to show the access from arbitrary projection angles. As stated in a
previous paragraph, this is very useful, as it is hard to define a standard view for these
vascular constructs of varying geometry [25]. A major asset of MR is its capability of a
functional evaluation of the access by measuring the flow rate [5]. Low values of the
access flow rate are indicative of increased risk of thrombosis [5,28-30], and may prompt
for radiological intervention in case of an underlying stenosis [6]. Ideally, when a low
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access flow is measured and the underlying stenosis is located by MRA, a PTA procedure
is done during the same procedure. Some attempts have been made to provide this one-
shop-stop approach with MRA [20].
The contrast agent used, Gd-DTPA, has an excellent safety profile and is considered at
least as safe as iodinated contrast agents [31]. Gd-DTPA is not contraindicated for use in
patients with impaired renal function [32,33], and can be removed by hemodialysis [34].
Finally, patients and physicians are not exposed to ionizing radiation.
A clear advantage of DSA over MRA is the possibility to perform the corrective interven-
tion on the spot, should a hemodynamically significant stenosis be detected. Techniques
for MR-guided endovascular interventions still have to be developed further to provide a
clinically attractive alternative [35]. In addition, a complete angiographic evaluation of
the graft or fistula on DSA includes visualization of the run off vessels to the superior
vena cava [25]. Indeed, several studies show that in a small number of patients stenoses
are found in the venous outflow tract [7,36]. A recent report indicates that images of the
run off veins of the extremities can be obtained using CE-MRA, as well [37]. The acquisi-
tion is started directly after intravenous injection of the contrast agent, instead of waiting
for the venous phase following the first arterial passage.
Although our study was not primarily focused on imaging of the outflow tract to the
superior vena cava, we nevertheless performed outflow tract examination by injecting 30
- 40 ml of diluted Gd-DTPA in 6 patients. Figure 5 shows an example of the CE-MRA of
an outflow tract. The results were quite promising. The total outflow tract was visualized
in a single scan, whereas a typical DSA outflow tract image would require at least two
images.
In conclusion, selective flow-interrupted CE-MRA imaging can provide excellent quality
images of hemodialysis AVF and AVG, which are free of flow artifacts. The high image
quality of the MR angiograms is comparable with DSA. In combination with MR flow
quantification and imaging of the outflow tract, our approach may provide a complete
anatomical and functional evaluation of hemodialysis accesses on MR.
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Abstract
Background. Efficacy of percutaneous transluminal angioplasty (PTA) is usually
expressed as the angiographic result. Access flow (Qa) offers a means to quantify the
functional effect. This study was performed to evaluate the short-term functional and
angiographic effect of PTA and to determine the longevity of the functional effect during
follow-up.
Methods. Patients with an arteriovenous graft (AVG) or fistula (AVF) eligible for PTA
(Qa < 600 mL/min) were included. Ultrasound-dilution derived Qa was measured short-
ly before PTA and periodically after PTA, starting 1 week after the procedure. The short-
term effect was expressed as the increase in Qa and as the reduction of stenosis. The
long-term effect was expressed as patency and as the decline in Qa after PTA.
Results. Ninety-eight PTA procedures in 60 patients (65 AVG, 33 AVF) were analyzed. Qa
improved from 371 ± 17 to 674 ± 30 mL/min in AVG, and from 304 ± 24 to 638 ± 51
mL/min in AVF (both P < 0.0001). In 66% (AVG) and 50% (AVF) flow increased to levels
> 600 mL/min. Degree of stenosis decreased from 65 ± 3% to 17 ± 2% in AVG and from
72 ± 5% to 23 ± 7% in AVF (both P < 0.005). Reduction of stenosis did not correlate
with ∆Qa (r2 = 0.066). Six-month unassisted patency after PTA was 25% for AVG and
50% for AVF. Decline in Qa was 3.7 ± 0.8 ml/min/day in AVG and 1.8 ± 0.9 ml/min/day
in AVF. Qa before PTA and ∆Qa correlated with the subsequent decline in Qa (P <
0.005).
Conclusions. Access flow increases after PTA, however in a substantial percentage not to a
level > 600 mL/min. Qa before PTA and the increase in Qa correlated with long-term
outcome, whereas angiographic results did not. The present data combined with the lit-
erature suggest that there is an optimal timing for PTA.
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Introduction
Vascular access complications account for considerable morbidity and mortality in
hemodialysis patients. In the United States they are responsible for up to 25% of all hos-
pitalizations in dialysis patients [1-3]. The European Dialysis and Transplant Association
does not collect data on this issue, but it is likely that data in Europe and elsewhere will
be comparable.
Thrombosis is the leading cause of vascular access complication. It is almost always asso-
ciated with the presence of stenosis. Percutaneous transluminal angioplasty (PTA) is an
accepted treatment of stenotic lesions [3]. Routine surveillance programs for the early
detection of stenoses followed by angioplasty have been shown to substantially reduce
the number of thromboses per patient year [4-7]. However, repetitive PTA treatment is
often necessary, since re-stenosis frequently occurs. Although the short term success rates
of PTA range from 85% to 98% [8], patency at 6 months follow-up varies from 38% to
63% [4,9-11].
Several studies have shown that angiographic degree of the stenotic lesion before and after
PTA is poorly related with its subsequent patency [9,11-14]. Recently, the SCVIR
Technology Assessment Committee recommended that PTA efficacy should be expressed
by both angiographic and functional parameters [15]. In particular, access flow (Qa) meas-
urements offer the opportunity to quantify and follow up the functional effect of PTA.
The purpose of this study is to assess access function of patients undergoing PTA. We
quantified the short-term functional and angiographic effect of PTA. Additionally, we
determined the longevity of the functional effect during follow-up. Finally, we addressed
the question whether functional variables are predictive for long-term outcome.
Patients and methods
This prospective observational intervention study was done in 9 Dutch hemodialysis
centers, in which a well-defined surveillance protocol was instituted as part of the routine
patient care. All chronic hemodialysis patients with permanent arteriovenous grafts
(AVG) and fistulae (AVF), who were referred for angiography because predetermined Qa
threshold levels were reached, were eligible to enter the study. The surveillance protocol
included periodic Qa measurements and angiography with PTA in thus selected patients.
Qa surveillance protocol
Qa was measured at least every 8 weeks using the ultrasound hemodilution technique
(Transonic Systems Inc, Ithaca NY). The bench and clinical validations are presented
elsewhere [16,17]. The surveillance protocol has been discussed in detail previously [7].
In brief, Qa determination consisted of the average of three single measurements within
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the first 30 minutes of the dialysis session at a fixed pump flow (> 200 mL/min). If Qa
levels reached values between 600 and 800 mL/min the measurement was repeated at
least every 4 weeks. Patients were referred for angiography whenever Qa was below 600
mL/min. Patients referred for angiography based on other criteria, for instance frequent
miscanulation, swelling of the arm or high venous pressure, were excluded. Patients with
a history of allergy to iodinated contrast agents were also not included into the study.
Angiography and percutaneous transluminal angioplasty (PTA)
Angiography and PTA procedures were done as soon as possible (usually < 7 days) after
the low Qa level (< 600 mL/min) was diagnosed. Digital subtraction angiography was
performed to visualize the complete vascular access and to locate the stenosis. Any lumi-
nal reduction of 50% or more was treated by percutaneous transluminal angioplasty
(PTA) during the same session. The same PTA technique was used for all patients. First,
the stenotic lesion was crossed with a guide wire (Boston Scientific Corporation,
Watertown, MA). Then a sheath was introduced (Cordis Europe N.V., Roden, The
Netherlands). The PTA balloon catheter was then passed over the guide wire to the loca-
tion of the stenosis. In general, the high-pressure balloons had a diameter of 6 mm
although larger balloons (up to 10 mm) could be used for large proximal veins (Bülach,
Switzerland). At the stenotic site the balloon was inflated to at least 10 atmospheres of
pressure and held for approximately 2 minutes. In resistant cases pressures up to 20
atmospheres were used and held for 10 minutes. No heparin, vasodilators or local anes-
thetics were given during the procedure. Immediately after PTA an angiogram was
obtained to evaluate the result of the procedure. The interventional radiologist consid-
ered the PTA procedure successful when the residual diameter of the stenosis was less
than 25%. After PTA, Qa measurements were done within one week and then at least at 4
weeks intervals. In case Qa fell below 600 mL/min, patients were referred for angiography
and repeat PTA was performed if necessary.
Outcome variables and statistical analysis
The short-term functional effect of PTA on Qa was evaluated by calculation of ∆Qa, i.e.
the difference between Qa before (Qapre) and just after PTA (Qapost). The long-term
functional effect was assessed as the time to the next intervention, if applicable. When
there were 3 or more Qa measurements after the PTA, the decline in Qa was determined
(in ml/min/day). Resistance was calculated as the ratio of mean arterial blood pressure
(MAP) and Qa. Angiographic data were analyzed by an independent radiologist. Only
cases that had adequate biplanar angiograms available of the stenotic areas both before
and after PTA were included. Stenosis degree was assessed before (baseline) and after
PTA (post-PTA) as the ratio of maximal lumen reduction and an adjacent normal
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graft/vessel diameter (expressed in percentage: 0% = no stenosis, 100% = occlusion).
Stenosis reduction due to PTA was calculated by the difference between baseline stenosis
and post-PTA stenosis.
Data are presented as mean ± SEM, unless indicated otherwise. Differences of Qa and
∆Qa values between different time points and subgroups of patients were calculated with
two-tailed t-tests. Pearson analysis was used for correlation purposes. Post-PTA primary
patency, i.e. the period of time that elapsed following intervention until access thrombo-
sis or re-intervention (surgical and/or radiological), was calculated using life-table analy-
sis. To compare post-PTA survival of AVF and AVG the (two-sided) log-rank test was
performed. P values of less than 0.05 were considered significant.
Results
Sixty patients referred for angiogram were included. A total of 98 PTA procedures were
performed. In 35 patients with an AVG, 65 PTA procedures were done. In the remaining
25 patients with an AVF, 33 PTA procedures were performed. Patient and graft character-
istics are shown in Table 1.
Functional results
Short-term. In all cases the first Qa measurement was done within 7 days after PTA, usu-
ally during the first dialysis session after PTA.
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Table 1. Patient and access characteristics 
AVG AVF Total
Patients 35 25 60
Mean age in years (range) 62.7 (37.2 - 82.6) 66.8 (34.6 - 83.7) 64.4 (34.6 - 83.7)
Gender
Male 6 16 22
Female 29 9 38
Diabetes 9 (26%) 4 (16%) 13 (22%)
Coumarin therapy 19 (54%) 10 (40%) 29 (48%)
Mean age access in days (range) 629 (2 - 1893) 1088 (30 - 2926) 806 (2 - 2926)
Lower arm / upper arm 31 / 4 21 / 4 52 / 8
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In AVG, Qa improved from 371 ± 17 to 674 ± 30 mL/min (P < 0.0001). MAP remained
stable after PTA (97 ± 2 vs 96 ± 2 mmHg), indicating that the increase in Qa represents a
decrease in resistance. Qapost values greater than 600 mL/min were reached in 62%
(40/65) (Figure 1A). A negative correlation was found between Qapre and the ∆Qa (P =
0.0019, r = -0.38). In diabetics Qapre did not differ from non-diabetics (340 ± 32 mL/min
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Figure 1. Qa results within one week after PTA in A.) AVG and B.) AVF (both P < 0.0001)
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versus 386 ± 19, P = 0.20). PTA in diabetics tended to be less effective than in non-dia-
betics (∆Qa, 228 ± 50 and 337 ± 41 mL/min respectively, P = 0.06). The age of the AVG
and of the patient did not correlate with ∆Qa. In 15 patients multiple procedures were
done (Table 2). In patients who were treated twice, ∆Qa was 355 ± 68 ml/min and 424 ±
79 ml/min after the first and second PTA respectively (n = 15, P = NS). In patients who
were treated 3 times, ∆Qa was 315 ± 98, 484 ± 112 and 345 ± 51 ml/min after the first,
second and third PTA respectively (n = 10, P = NS). In 15 patients, the PTA was the first
intervention on the AVG. ∆Qa in those patients did not differ from those who had a sec-
ond or later PTA (287 ± 61 vs. 313 ± 41 mL/min, P = 0.72). Unassisted patency did not
differ either.
In AVF, Qa improved from 304 ± 24 to 638 ± 51 mL/min (P < 0.0001) (Figure 1B), 52%
(17/33) of PTA procedures resulted in Qapost levels of more than 600 mL/min. The ∆Qa
was not related to Qapre in AVF (r = -0.06). Diabetes or age of the AVF or patient did not
significantly affect the results in AVF. Only four patients underwent 2 PTA procedures
(Table 2) and showed a ∆Qa of 541 ± 173 mL/min and 285 ± 144 mL/min after the first
and second PTA respectively (P = 0.09).
Long-term. In 35% of all patients (21/60) multiple procedures were performed. In AVG,
repeat PTA was more common than in AVF (43% (15/35) versus 24% (6/25) Table 2). In
AVG, the mean time interval to re-PTA was shorter than in AVF (109 ± 12 and 169 ± 32
days, P = 0.04). In those with two PTA procedures, time interval between the first and
second PTA was 113 ± 18 days (n = 15). In those with three PTA procedures, time inter-
val between the first and second and second and third PTA was 122 ± 26 and 101 ± 21
days respectively (n = 10, P = NS).
Decline in Qa after PTA was 3.7 ± 0.8 ml/min/day in AVG (n = 38) and 1.8 ± 0.9
ml/min/day in AVF (n = 24) (P = 0.06). Coumarin use and diabetes did not affect the
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Table 2. Number of patients with single and multiple PTA procedures
AVG AVF Total
Single PTA 20 (20) 19 (19) 39 (39)
Multiple PTA 15 (45) 6 (14) 21 (59)
2 5 (10) 4 (8) 9 (18)
3 6 (18) 2 (6) 8 (24)
4 3 (12) - 3 (12)
5 1 (5) - 1 (5)
Total 35 (65) 25 (33) 60 (98)
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decline in Qa after PTA. However, there was a correlation between Qapre levels and the
subsequent decline in Qa after PTA (r = -0.43, P < 0.005). Also, ∆Qa correlated with the
decline in Qa after PTA (r = -0.48, P = 0.0009).
The median primary patency after PTA in AVG was 97 days. The post-PTA primary
patency rates for AVG were at 1, 3 and 6 months 100%, 56% and 25% respectively. The
median patency of AVF was 161 days. Post-PTA primary patency rates for AVF were at 1,
3 and 6 months 100%, 92% and 50% respectively.
Log-rank comparison analysis of intervention-free survival curves demonstrated a sig-
nificant difference in favor of the AVF (P = 0.031).
During the available follow-up period no unpredicted thrombotic events (i.e. accesses
thrombosed with a Qa > 600 mL/min) occurred. In 6 AVG with a Qa that remained
below 600 mL/min after PTA, thrombosis occurred within weeks after PTA. These are
considered predicted thromboses. Furthermore, some thromboses occurred in patients
with low Qa while waiting for PTA. These accesses were not included in this analysis,
because no PTA procedure was performed.
Angiographic results
In AVG, 48 (74%) PTA procedures were performed on single lesions (38 (58%) venous, 9
(14%) midgraft, and 1 (2%) arterial stenosis). Seventeen (26%) PTA procedures were
done on two stenotic lesions (12 (18%) showed a venous and midgraft stenosis, and 5
(8%) had an arterial and venous stenosis). Log rank survival analysis showed no differ-
ence in patency between AVG with a single lesion versus those with multiple lesions (P =
0.74). Seven (21%) PTA procedures in AVF were of true anastomotic lesions, twenty
(61%) were performed on venous lesions (in most cases located within the first few cen-
timeters from the anastomosis) and 6 (18%) on combined (venous and anastomotic)
lesions. In 92% of all PTA procedures, angiographic improvement of the stenosis was
achieved using a 6-mm balloon. Larger balloons were occasionally needed for proper
dilatation of stenoses in proximal AVF veins. In all cases PTA was reported to be success-
ful, i.e. residual luminal reduction of 25% or less.
In AVG, baseline stenosis was 65 ± 3% and post-PTA stenosis 17 ± 2% (n = 33, P <
0.0001). No correlation was found between baseline stenosis and post-PTA stenosis (r = -
0.14, P = 0.47) or Qapost (r = -0.05, P = 0.76). Baseline stenosis correlated with Qapre (r =
-0.48, P = 0.008). No correlation was found between angiographic (i.e. stenosis reduc-
tion) and functional (∆Qa) improvement (r2 = 0.066) or between baseline stenosis and
subsequent decline in Qa (r = -0.02, P = 0.93). Additionally, neither the stenosis reduc-
tion (P = 0.29) or the post-PTA stenosis (P = 0.07) correlated with the decline in Qa after
PTA. Log rank survival analysis of the lower and upper 50th percentile baseline stenosis
revealed no difference in survival (P = 0.90).
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When the AVG group was divided in a group with Qapost < 600 mL/min (n = 24) and a
group with Qapost > 600 mL/min (n = 41), we found that there was no difference in
angiographic results between both groups. The group with Qapost < 600 mL/min showed
a stenosis of 66 ± 4% before and 19 ± 4% after PTA, while the group with Qapost > 600
mL/min had a stenosis of 63 ± 4% before and 14 ± 3% after PTA (P = NS). The group
with Qapost < 600 mL/min had a Qapre of 336 ± 24 mL/min and a Qapost of 441 ± 22
mL/min (∆Qa = 105 ± 24 mL/min). Those with Qapost > 600 mL/min had a Qapre of 392
± 22 mL/min and a Qapost of 811 ± 29 mL/min (∆Qa = 419 ± 40 mL/min). Of the 24
patients with Qapost < 600 mL/min, 6 thrombosed within 4 weeks after PTA, 8 had a sur-
gical correction without repeat angiogram, in 10 cases repeat angiograms showed 61%
stenosis. Two of those patients were subsequently referred for surgical revision, and eight
had another PTA.
For the AVF, baseline stenosis was 72 ± 5% and post-PTA stenosis was 23 ± 7% (n = 8, P
= 0.0039).
Discussion
To our knowledge this is the first study in AVG and AVF reporting both angiographic and
functional results of PTA. The present data contain novel information. We show that
angiographic results do not correlate with functional results. Importantly, we demon-
strate that functional variables are predictive for long-term outcome, whereas angio-
graphic results are not. The study confirms recent data indicating that PTA results in a
direct increase in Qa of approximately 250 mL/min [18]. We also confirm that a substan-
tial percentage of PTA is not successful. Finally, time to repeat PTA in the present study is
substantially shorter than in other studies [9,18,19]. This suggests a more rapid recur-
rence of stenosis in the present study. The combined data of these studies suggest that
there is an optimal moment of PTA.
Based on the vast experience reported in the literature the NKF-K/DOQI taskforce has
suggested PTA as one of the preferred treatments of vascular access stenosis [3]. In most
studies, the post-PTA stenosis is used to express the efficiency of a PTA procedure.
However, the post-PTA stenosis poorly predicts patency after PTA [9,11-14]. Recently,
the SCVIR Technology Assessment Committee recommended reporting both angio-
graphic and functional data as efficacy variables of PTA [15].
Our patients all had a Qa below 600 mL/min, which especially in grafts is a strong pre-
dictor for imminent thrombosis [3,20-23]. They all had a baseline stenosis of 50% or
more, which was treated by PTA. We confirm earlier data that on average Qa increases
with approximately 250 - 300 mL/min [18,24]. In the patients with adequate
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angiograms, the post-PTA stenosis in AVG was in almost all cases 25% or less. This is
considered to be an adequate angiographic result [3]. However, the decrease in resistance
did not correlate with the stenosis reduction, indicating that angiographic improvement
does not necessarily represent functional improvement. Preliminary data in a small
group of patients also indicated that the stenosis reduction did not correlate with the
increase in Qa [14]. Results in diabetics did not differ from those in non-diabetics. The
percentage of PTA procedures resulting in a Qapost above the threshold value of 600
mL/min, was 66% in AVG and 50% in AVF. Schwab et al. defined failure of PTA as an
increase in Qa of less than 20%, which occurred in 21% of grafts [18]. This lack of effect
may be caused by rapid recoil of the stenotic lesion, occurring in the period between PTA
and first Qa measurement. Intravascular ultrasound after PTA showed that immediate
elastic recoil occurred in 50% of the stenotic lesions [25]. The present findings may also
indicate that other stenotic lesions, which importantly contribute to overall resistance,
were not identified and not treated. Qa measurements during or immediately after PTA
in the intervention room could be helpful to optimize procedure results [24].
In patients who needed multiple procedures, similar increases in Qa were obtained in
subsequent PTA procedures. This finding supports earlier data indicating that patency
after repeat PTA does not decrease [9]. Lumsden et al. randomized patients with greater
than 50% stenosis to have either a PTA or no PTA and found that outcome did not differ
[12]. Later the same authors re-analyzed their data and reported that patency did
improve but only in grafts without prior angioplasty or thrombosis [13]. In the present
study only in a minority of AV grafts, the PTA included in this study was the first inter-
vention. We were unable to confirm the earlier results, that outcome of a first interven-
tion is better than that of a second or later intervention.
Usually, long-term results of PTA are quantified as primary patency. In AVG, it varies
from 38 - 64% at 6 months and 10 - 40% at 12 months [8]. We found an intervention-
free primary patency at 6 months of 25% in AVG. The median time to next PTA was 97
days, as compared to 5.8 months in the study by Schwab et al. [18]. Their results seem
substantially better than the present results, whereas the short-term functional effects in
the two studies are comparable. Some of the differences between these studies may be
important in this respect. In the present study, AV grafts were almost exclusively localized
in the lower arm, whereas Schwab’s study mainly included upper arm AVG. We selected
patients when the threshold of 600 mL/min was reached, whereas in the other study most
patients were referred when Qa showed a decrease of more than 20% or more. As a
result, both Qa before and after PTA differed considerably, i.e. in the present study 371 ±
17 to 674 ± 30 mL/min and in the previous study approximately 750 and 950 mL/min
[18]. The decline in Qa after PTA correlated with the Qapre level, suggesting that the
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severity of stenosis before PTA is predictive for the rate of stenosis recurrence. In patients
with a Qapre level between 100 and 350 mL/min the decline in Qa was 4.1 ± 1.0
ml/min/day versus 2.7 ± 1.2 ml/min/day for the patients with a Qapre level between 350
and 600 ml/min. Further support for this notion comes from patients who underwent
PTA because of high venous pressure and who were not included in this study. In these
patients (n = 12) who had Qapre levels between 600 and 800 ml/min, the decline in Qa
was 1.6 ± 1.8 ml/min/day, which perfectly corresponds with the 5.8 months between
consecutive interventions as reported by Schwab et al. [18]. Whereas baseline stenosis
correlated with Qapre, post-PTA results (both post-PTA stenosis and stenosis reduction)
did not correlate with the subsequent decline in Qa. These data suggest that Qa and
therefore resistance is more predictive for longevity of effect of PTA than the angio-
graphic variables.
Also, the correlation between the ∆Qa and the decline in Qa deserves comment. It is like-
ly that a higher ∆Qa is an indication of a greater dilation of the stenosis, probably corre-
sponding with more tissue injury. This may favor more rapid stenosis recurrence. Indeed,
there is some indication that a less traumatic dilation, for instance by a cutting balloon,
results in less activation of growth factors (reviewed in [23]).
The combined results of the present study and the study by Schwab et al. [18] warrant
the start of a new discussion on the optimal timing of PTA. It is tempting to hypothesize
that post-PTA patency in AVG is related to Qapre and/or the functional result of the PTA.
If this turns out to be the case, PTA should be done as soon as a decrease in Qa is found,
as is advocated by some [18,26], instead of when a low Qa level is reached as is proposed
by others [7,27]. In such cases a “mild” PTA may result in a better long-term outcome
than a more vigorous one. Quality of patient care and cost effectiveness of PTA may ben-
efit importantly from properly designed studies addressing this hypothesis.
Possibly the best way of quantifying the long-term effect of PTA is by calculating second-
ary patencies. However, the present study was not designed to address this question.
Many patients were included in the surveillance and intervention program of the present
study long after the day they had the access implanted. Some of them had undergone
interventions before their inclusion in the study, making it impossible the express true
secondary patency of AV grafts followed by the surveillance and intervention program as
in the present study. However, survival estimation of our secondary patency rates for
AVG revealed a 6-month patency of 85%, a 1-year patency of 79%. In AVF, survival
analysis showed a 6-month patency of 89% and a 1-year patency of 82%. With the limi-
tation outlined above in mind, we can conclude that our secondary patency is compara-
ble to the data in the literature on secondary patency rates [3,8].
63
Access function after PTA
hoofdstuk 05  09-10-2001  10:04  Pagina 63
The association between Qa and risk for thrombosis in AVF is less well documented than
in AVG. AVF with Qa levels less than 300 to 500 mL/min can still remain patent [3].
K/DOQI recommends that AVF should be monitored as AVG. The efficacy of PTA in
AVF was comparable to that in AVG. The long-term effect in AVF seems substantially
better than in AVG. Primary (post-PTA) patency in AVF ranges from 47 - 67% at 6
months and 16 - 62% after 12 months [8]. We found intervention-free primary patencies
at 6 months of 50% and a median survival of 161 days for AVF. None of the investigated
variables were predictive for the long-term result in AVF.
In conclusion, access flow increases after PTA, however in a substantial percentage not to
a level > 600 mL/min. Qa before PTA and the increase in Qa correlated with long-term
outcome, whereas angiographic results did not. The present data combined with the lit-
erature suggest that there is an optimal timing for PTA.
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Abstract
Background. Percutaneous thrombolysis has become an accepted treatment of throm-
bosed hemodialysis grafts. Several devices have been developed for mechanical throm-
bolysis, which macerate the clot using different mechanisms such as aspiration and
fragmentation. The aim of our study was to compare the efficacy of three devices for
mechanical thrombolysis in removing thrombus from thrombosed hemodialysis access
grafts and to determine the initial technical and clinical success, complication rates of
each device, and graft patency after the procedure.
Methods. Thrombolysis (i.e. clot removal followed by percutaneous transluminal angio-
plasty (PTA)) was performed in 68 thrombosed hemodialysis grafts using the Cragg
brush catheter combined with urokinase in 13, the Hydrolyser in 18 and the Arrow-
Trerotola PTD in 37. Clot removal scores (CRSs, the ability to thoroughly remove clot
from the access), initial technical success, clinical success, patency at 30, 60 and 90 days
and complication rates were evaluated.
Results. CRSs for the Cragg brush, Hydrolyser and PTD were good in 92%, 44% and
95% of cases, respectively. Initial technical (85%, 83%, 95%) and clinical success (62%,
67%, 86%), mean patency rates at 30 (73%, 60%, 55%), 60 (61%, 53%, 49%) and 90
(49%, 40%, 43%) days, stenosis after PTA (33%, 46%, 21%) and complication rates (8%,
6%, 0%) were not different for the three devices. Success rates and graft patency depend-
ed on the effect of PTA, irrespective of the device used.
Conclusions. The rotational devices removed clot more effectively than the Hydrolyser,
with the PTD having the advantage of not requiring urokinase. However, the result of
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Introduction
Percutaneous thrombolysis has become an accepted treatment of thrombosed hemodial-
ysis grafts [1]. A number of techniques have been described. In pharmacological throm-
bolysis a lytic agent such as streptokinase or urokinase is administered intravenously or
directly into the graft [2]. With pulse spray pharmacomechanical thrombolysis, lysis is
accelerated by injecting the lytic agent into the clot, using a dedicated multi side hole
infusion catheter [3,4]. More recently, mechanical devices have been developed for
mechanical thrombolysis which macerate the clot using different mechanical actions
such as aspiration and fragmentation [5].
Comparison of the efficacy of these devices is difficult. Most studies report on a single
device only. Thrombolytic devices may be effective in removing thrombus material, how-
ever, they do not treat the underlying causes for clot formation, i.e. stenoses compromis-
ing blood flow [6-10]. Often, patency rates are given as a measure for determining
efficacy of mechanical devices. However, patency of a graft after mechanical thrombolysis
is likely to depend on the result of the treatment of the underlying stenoses [11,12], and
clot removal is only part of the treatment. Comparison of reported procedure times and
complication rates is also difficult because the methods vary among institutions, and dif-
ferences in study results are therefore difficult to assess.
Over the last four years we applied three techniques for thrombolysis of hemodialysis
grafts using mechanical devices for clot removal. The goal of our study was to compare
the efficacy of each method in removing thrombus from hemodialysis access grafts and
to determine the initial technical and clinical success, complication rates of each device,
and graft patency after the procedure.
Patients and methods
All patients with a thrombosed vascular access graft were eligible to enter the study.
Informed consent was obtained from all patients. The study was approved by the insti-
tute’s Medical Ethical Committee. In its original design it was a prospective study to eval-
uate the efficacy of the rotating brush catheter. However, when this device was
withdrawn by the manufacturer, a second (the hydrodynamic catheter) and later a third
device (rotating basket catheter) were prospectively examined.
Clot removal procedures
All procedures were performed with the crossed catheter technique [13]. Access puncture
was performed under local anesthesia with lidocaine 2%. In the standard procedure, no
sedatives, systemic analgesics or antibiotics were used. In one third of cases ultrasonogra-
phy was used at the operators discretion to guide puncture of the graft. A guide wire was
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advanced and navigated across the venous anastomosis. Subsequently, a sheath was
introduced towards the venous anastomosis (venous sheath). By contrast agent injection
through a straight catheter, the central venous outflow tract and venous anastomosis of
the graft were evaluated for the presence of stenoses. Also, the central end of the throm-
bus was determined. A second sheath was then introduced towards the arterial anasto-
mosis (arterial sheath). Care was taken to avoid overlap of the sheaths. The actual
thrombus treatment was then initiated using one of the following mechanical devices
(chronological order).
Rotating brush catheter (Cragg brush)
The first mechanical device exploited was the Cragg brush catheter (Cragg Thrombolytic
Brush, Micro Therapeutics, San Clemente, CA). Before employing the Cragg brush
catheter 125.000 IU of urokinase mixed with 5000 IU heparin in 20 ml saline was inject-
ed into the clotted graft with the pulse-spray technique using a multi-side hole infusion
catheter (Cook Inc, Bloomington, IN) [14]. During slow withdrawal of the brush and
catheter, an additional 125.000 IU of urokinase mixed with 60 ml of 1:1 diluted iodinated
contrast agent (30 ml per limb) were administered through a sidearm of the catheter,
allowing real time visualization of clot fragmentation and subsequent restoration of the
graft lumen. When the Cragg brush was temporarily withdrawn from clinical tests
because of technical problems, we started to use a hydrodynamic catheter.
Hydrodynamic catheter (Hydrolyser)
The second device we employed for mechanical thrombolysis was a hydrodynamic
catheter (Hydrolyser, Cordis Europa NV, Roden, The Netherlands). The Hydrolyser con-
sisted of a 7-F double-lumen catheter with a 6-mm side hole at the tip [15,16]. The
device was introduced over a 0.025-inch guide wire. Saline was injected with a power
injector through the smaller of the two lumens. The resultant high-velocity jet was
directed retrogradely in the catheter, along the side hole into a wider discharge channel.
Due to the resultant underpressure (Venturi effect) the thrombus was aspirated into the
side hole, fragmented and evacuated via the discharge channel. The injection of 150 ml
saline at a flow rate of 4 ml/s resulted in an activation time of 37 seconds per run, during
which the catheter was slowly withdrawn. Each limb of the graft was treated with a mini-
mum of two runs. Any residual clot was removed by repeated passes with the Hydrolyser.
Rotating basket catheter (PTD)
In the third period, mechanical thrombolysis was performed with a rotating basket
(Arrow-Trerotola Percutaneous Thrombolytic Device, PTD. Arrow International,
Reading, PA). The PTD incorporates a self-expandable basket made of Nitinol wires,
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attached to a drive cable. It was described in detail previously [17]. The PTD was intro-
duced in its closed position through the sheaths. Once in place, the PTD was deployed.
The PTD was rotated by a handheld disposable motor unit at 3,000 rpm and slowly with-
drawn. After each pass, the PTD was removed in the deployed position and thoroughly
cleaned and flushed before closure. The slurry was aspirated and small amounts of con-
trast material were injected to evaluate the effectiveness of mechanical thrombolysis in
the venous limb. The arterial limb was then treated in the same way. The white clot at the
arterial anastomosis was removed with the PTD and not with a separate Fogarty
thrombectomy catheter. This modification of the original technique has recently been
described [17,18]. Any residual clot was removed by repeated PTD passes or, if unsuc-
cessful, by mobilization of residual clot using a slightly inflated balloon catheter.
PTA procedure
PTA was performed immediately following mechanical thrombolysis when a stenosis
greater than 50% of the vessel diameter was present. We routinely used 6-mm diameter
balloon catheters (Opta, Cordis Europa NV, Roden, The Netherlands) for intragraft
stenoses. For PTA at the anastomoses the size of the balloon was adapted to the size of
the artery and vein. Balloon catheters were inflated at maximum pressure of 12 ATM.
Attempts were made to achieve the greatest stenosis reduction possible. In case of recoil,
repeated PTA was performed with an oversized balloon. When the balloon did not
unfold because of rigidity of the stenosis, a non-compliant high-pressure balloon was
used with pressures up to 20 ATM. (Blue Max, Boston Scientific Corporation,
Watertown, MA). Angiography was performed at the end of each procedure. Patients
were scheduled for additional angiography and PTA within two weeks after the proce-
dure in case flow in the graft was restored only moderately because of considerable resid-
ual thrombus and/or unsatisfactory effect of balloon dilation.
Definitions
Success of treatment was assessed by angiography. Using a two-point scale, the clot
removal score (CRS) allowed discrimination between complete (successful) clot removal
(minimal to no residual clot, CRS = 1) and incomplete clot removal (considerable residual
thrombus material, CRS = 0). Minimal residual clot was defined as non-circumferential
wall-adherent thrombus involving only a small portion (one third or less) of the graft.
Any clot greater than minimal was graded as considerable. Initial technical success was
defined as the restoration of flow within the graft at the end of the procedure, thus after
clot removal and PTA. This criterion was met when a test bolus of iodinated contrast
material disappeared rapidly with the blood stream. Clinical success was defined as at least
one successful hemodialysis session using the graft after mechanical thrombolysis.
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PTA results were measured on hardcopy images. For intragraft stenoses and stenoses at
the anastomoses, the diameter in the stenosis was compared to the diameter of the graft.
For native vein stenoses, the diameter in the stenosis was compared to the diameter of a
non-stenotic part of the vein. Stenoses with a diameter reduction of more than 50% were
treated with PTA. The result of PTA was expressed as the percent residual stenosis after
PTA. When more than one stenosis was present, the part with the highest grade of resid-
ual stenosis was taken for residual stenosis rate of that graft.
Major complications were defined as: major bleeding necessitating surgery or transfu-
sion, symptomatic pulmonary or arterial embolization, severe contrast agent reaction,
injury to the graft necessitating surgery and mechanical defects of the device affecting
technical success [17]. Minor complications were defined as: minor contrast agent reac-
tion, adverse reactions to urokinase, asymptomatic arterial or pulmonary embolization,
self-limited hematomas treated by local compression and mechanical defects of the
device that did not affect technical success.
Total procedure time was defined as the time from beginning of local anesthesia, given at
initiation of the procedure until completion of hemostasis, applied to the graft at the end
of the procedure.
Primary patency rate was defined as the percentage of grafts that functioned well without
any additional intervention for graft failure. Follow-up time was censored for patients
who died or were otherwise lost to follow-up and patients who received a kidney trans-
plant.
Statistical methods
The difference in proportion with successful clot removal was calculated, including 95%
confidence intervals (CI). Ordinal data were analyzed by means of Chi-square tests.
Multiple logistic regression analysis was used to assess the independent association of
various clinical parameters. Primary patency was studied using Kaplan-Meier survival
curves. Differences in the patency rates were tested using the log rank test. In addition,
Cox’s proportional hazards model was used to analyze primary patency in relation to the
various clinical parameters comparable to the multivariate analysis of clinical success.
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Results
Between January 1996 and January 2000, 73 consecutive cases (60 patients) with a
thrombosed hemodialysis access graft were referred for mechanical thrombolysis, con-
sisting of clot removal followed by percutaneous transluminal angioplasty (PTA).
In five of the 73 cases, the procedure was ended before clot removal had begun, as the
venous anastomosis (n = 4) or the arterial anastomosis (n = 1) could not be passed with
a guide wire. Mechanical thrombolysis was performed in the remaining 68 cases (55
patients) (Table 1). Thirty-eight of the 68 access sites were PTFE grafts (Gore-Tex; Gore,
Flagstaff, Ariz.) and 30 were homologous vein grafts (Varivas; Vascogref BV, Bussum, The
Netherlands) (Table 1). Table 1 shows type and location of the grafts and the distribution
of graft material in the three device groups. In 67 of 68 cases mechanical thrombolysis
was completed; in one case clot removal was terminated because of technical failure of
the device. In 66 of 67 cases PTA followed clot removal. In the remaining case there was
no identifiable stenosis requiring PTA. The mean period grafts had been functioning was
15 months (range 3 - 60 months). Mechanical thrombolysis was performed between 8
hours and two weeks after diagnosing graft thrombosis, and in the vast majority (50
cases) treatment was started within 24 hours.
73
Percutaneous thrombolysis
Table 1. Number, type and location of grafts with distribution per device 
Device
Total Cragg Brush Hydrolyser PTD
Number of grafts 68 13 18 37
patients 55 13 14 28
Vein* PTFE‡ Vein PTFE Vein PTFE Vein PTFE
Type of graft 30 38 11 2 13 5 6 31
Location of grafts
Fore-arm loop 25 28 11 - 9 2 5 26
Upper arm loop 3 2 - - 3 - - 2
Axillo-axillary - 6 - 2 - 3 - 1
Fore-arm straight 2 2 - - 1 - 1 2
* homologous vein graft
‡ polytetrafluoroethylene
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Clot removal
Clot removal scores are shown in Table 2. The rotational devices (Cragg brush catheter
and PTD) had a similar clot removal score (92 versus 95%). Both had a significantly (P <
0.05) better clot removal score than the non-rotational device (Hydrolyser, 44%). CRS
was not associated to initial technical success (P = 0.72). In univariate analysis, CRS
seemed to have a significant association with clinical success (odds ratio 4.3, 95% CI 1.2 -
16). Using multivariate regression analysis, however, the association between residual clot
material and clinical success could not be confirmed. Cox proportional hazard analysis
revealed no relation between clot removal score and primary patency.
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Table 2. Results of mechanical thrombolysis by device 
Device
Cragg Brush Hydrolyser PTD
Clot Removal Score*
1 92% (11/12)‡ 44% (8/18) 95% (35/37)
0 8% (1/12) 56% (10/18) 5% (2/37)
Initial technical success 85% (11/13) 83% (15/18) 95% (35/37)
CI† 55 - 98% 59 - 96% 82 - 99%
Clinical success 62% (8/13) 67% (12/18) 86% (32/37)
CI 32 - 86% 41 - 87% 71 - 96%
Patency at 30 days 67% ± 14¥ 50% ± 12 52% ± 8
60 56% ± 15 39% ± 12 46% ± 8
90 44% ± 16 33% ± 11 40% ± 8
Mean procedure time (min) 118 ± 27 132 ± 16 119 ± 43
Range 80 - 150 105 - 150 70 - 168
Major complications 8% (1/13) 6% (1/18) 0%
Minor complications 31% (4/13) 56% (10/18) 43% (16/37)
Mean number of stenoses per grafts 2.2 2.5 1.9
Note.- Thirteen brush procedures; in one procedure the brush broke off, so twelve clot removal scores remained. For
calculation of success rates and patency, the broken brush was considered as a failure.
* CRS 1 = minimal to no residual thrombus. CRS 0 = considerable residual thrombus.
‡ numbers of patients are given in parentheses
† CI = 95% confidence interval
¥ standard error of the mean
hoofdstuk 06  09-10-2001  10:03  Pagina 74
Initial technical success and clinical success
Cragg brush
Initial technical success was achieved in 11 (85%) of the 13 patients (Table 2). In one case
the brush broke off before clot removal was completed and in another case blood flow
could not be restored because of bleeding complications after clot removal. Successful
hemodialysis after mechanical thrombolysis could be performed in 8 of 13 patients, indi-
cating a clinical success rate of 62%. In three of the 11 patients with initial technical suc-
cess, re-occlusion of the grafts occurred before the first post-procedural hemodialysis
following mechanical thrombolysis could be performed.
Hydrolyser
Initial technical success was reached in 83% (15 of 18 cases). In the remaining three,
restoration of blood flow could not be achieved because of a long rigid stenosis in the
native vein of the upper arm, which was resistant to PTA (n = 1); a 60% residual stenosis
with a small dissection after PTA at the arterial anastomosis (n = 1); and bleeding com-
plications during mechanical thrombolysis that was performed one-day after shunt revi-
sion (n = 1). In three of the remaining 15 cases with initial technical success, re-occlusion
of the grafts occurred before the first hemodialysis following mechanical thrombolysis
could be performed, resulting in a clinical success rate of 67% (12/18 cases).
PTD
With the PTD, the initial technical success was 95% (35/37 cases). In one of the two
unsuccessful cases, restoration of blood flow could not be achieved due to a rigid stenosis
at the arterial anastomosis resistant to PTA, and in the other one there was occlusion of
the graft by overlapping sheaths and residual white clot material. In three of the 35 cases
with initial technical success, re-occlusion of the grafts occurred before the first post-
procedural hemodialysis could be performed, resulting in a clinical success rate of 86%
(32/37 cases).
Using multivariate logistic regression analysis and Cox’s regression analysis respectively,
no association was found between type of device used and clinical success and between
type of device used and primary patency.
Distribution and treatment of stenoses
A total of 142 stenoses were encountered in 67 grafts treated. Sixty-two of the 67 grafts
showed a stenosis at the venous anastomosis (93%) and 29 at the arterial anastomosis
(43%). Twenty-three (34%) were located in the upper arm and central vein and 28
stenoses were in the graft itself (42%). Mean number of stenoses was 1.8 in the PTFE
group and 2.5 in the homologous vein group. As is shown in table 1, there was an uneven
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distribution of types of graft material in the three device groups. Accordingly, the num-
ber of stenoses per device group was also distributed unevenly. The mean number of vas-
cular stenoses per graft in the Cragg brush group, the Hydrolyser group and the PTD
group were 2.2, 2.5 and 1.9 respectively.
In fourteen of 67 cases PTA of the underlying stenosis resulted in residual stenosis of
more than 50% (mean 75% residual stenosis, range 55 to 99% residual stenosis). Six of
seven procedures with initial technical failure were found in the last group. Seven cases
were scheduled for control angiography because of unsatisfactory results due to the pres-
ence of residual clot and/or stenosis after the procedure. Four of these cases showed clini-
cal evidence of re-occlusion within 24 hours. These were not re-entered in the study. The
other three cases were evaluated with angiography 6 - 14 days after the procedure. All
three showed complete resolution of residual clot. One of the three showed 60% residual
stenosis, which was treated with PTA. One case showed 55% residual stenosis which was
not treated and one showed no residual stenosis.
Independent of the type of device used, multiple logistic regression analysis showed a
strong relationship between residual stenosis and clinical success (odds ratio 0.92, 95%
C.I. 0.87 - 0.96). Cox’s regression analysis also showed that residual stenosis was the only
parameter that determined follow-up.
Complications
Cragg brush
One major complication occurred: the brush broke off its drive cable at the curve of the
loop graft during withdrawal of the brush. The loose brush was retrieved using a goose
neck catheter with successive graft damage. Four minor complications included rupture
of the venous anastomosis after PTA (n = 1), asymptomatic retrograde arterial
embolism, which was treated with additional local urokinase infusion (n = 1), and spon-
taneous hematomas occurred in two cases at previously used puncture sites for
hemodialysis. These hematomas were treated with manual compression.
Hydrolyser
One patient had symptomatic, scintigraphically proven pulmonary embolism. Minor
complications occurred in ten cases. These included seven patients with a total of nine
hematomas. Two of these nine hematomas were caused by unsuccessful needle punctures
of the graft at the beginning of the procedure. Three of the nine hematomas occurred at
PTA sites. In three patients asymptomatic retrograde arterial emboli were seen at control
angiography after mechanical thrombolysis. These three patients showed no clinical
signs; the emboli were not treated and there were no long-term sequelae.
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PTD
No major complications occurred in the 37 cases treated with the PTD. Minor complica-
tions occurred in 16 with 9 of those experiencing minor bleeding. In four of these 9
cases, there were hematomas at prior puncture sites. In the remaining five, minor bleed-
ing occurred at the site of balloon dilation, which were treated by local manual compres-
sion. Minor mechanical problems with the device occurred in seven cases. In three of
these, one of the wires of the PTD broke at the proximal connection. A broken wire ham-
pered withdrawal of the PTD in the covering catheter. In two cases, the 5-F guiding
catheter, in which the PTD was housed, wrinkled near the motor unit and in two other
cases, the cover catheter broke. These mechanical defects occurred chiefly in the first half
of the procedures and were less common after the manufacturer had modified the basket
and its housing catheter.
Procedure time
As shown in Table 2 procedure times were comparable for each type of device. Length of
the procedure as such was mainly determined by the number of stenoses (r = 0.47).
Patency rates
Mean survival time was 144 ± 31 days (median 59 days). Ten patients were lost to follow-
up. Six of them died. Five of these six died as a result of unrelated disease 6 to 790 days
after the procedure with an intact shunt. One patient died four days after mechanical
thrombolysis due to sepsis, which was thought to be related to central catheters, but may
also have been related to shunt infection. Four patients were censored because of renal
transplant, 22 to 377 days after the procedure. Figure 1 shows the Kaplan-Meier survival
curves of each device (P = NS). Primary patency rates are shown in table 2. For all proce-
dures, primary patency rates were 53 ± 6% at 30 days, 46 ± 6% at 60 days and 39 ± 6% at
90 days. Using Cox’s proportional hazard model, long-term patency rates were signifi-
cantly related to residual stenosis (hazard ratio 1.025, 95% CI 1.009 to 1.041), meaning
that each percent of rest stenosis induces a risk for graft failure of 2.5% (CI 0.9 - 4.1%)
per day. Patency rates were not related to type of device nor to clot removal score.
Discussion
In this study, in which we evaluated three devices used for mechanical thrombolysis, we
found that the rotating devices -the Cragg brush and the PTD- performed significantly
better than the Hydrolyser in removing thrombus from hemodialysis access grafts. When
applying the Cragg brush or the PTD, the original contour of the graft wall was restored.
Removal of thrombus with the aid of the Hydrolyser often resulted in an irregular lumen
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with residual thrombus material adherent to the wall. The most likely explanation for the
superior clot removal scores that the rotating devices achieved is that both use the same
principle of a self-expanding wall-contact mechanism, in which the device is centered in
the vessel lumen with the device’s hairs or wires rubbing against the vessel wall to remove
the clot [19]. The main action of the Hydrolyser, however, is exerted through the side
hole of the catheter, often resulting in removal of only the clot facing the side hole and
leaving the remaining clot in place. As a result, thrombus removal achieved with the
Hydrolyser frequently is incomplete. Vesely et al. showed similar results with respect to
thrombus removal between the different devices. However, no patency rates were given
for their thrombolysis procedures [19].
Using univariate analysis, we found that successful clot removal seemed to be associated
with clinical success. However, after adjusting for residual stenosis, the association with
clot removal could not be confirmed. In addition, there was no association between clot
removal and long-term patency. These results add to the discussion of the relevance of
residual thrombus in the graft after clot removal [20,21]. Large fragments of residual clot
will obstruct the lumen and hamper initial technical success. These large fragments can
easily be identified and removed using additional mechanical thrombolysis or by means
of the balloon catheter. Small amounts of residual clot appeared to be insignificant
because they disappeared completely 1 to 2 weeks after treatment. This refers to the
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Figure 1. Kaplan-Meier survival curves of mechanical thrombolysis using the Cragg Brush, the Hydrolyser and the
PTD. The curves were not significantly different.
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inherent thrombolytic capability of the normal bloodstream and, probably, is the result
of adequate restoration of blood flow through the graft.
Percutaneous transluminal angioplasty (PTA) adds substantially to initial technical suc-
cess [3,8,22]. In our study, using Cox’s regression analysis, residual stenosis after PTA
appeared to be the single, most important factor predictive of primary patency after
mechanical thrombolysis. Therefore, we believe that the main goal of a mechanical
thrombolysis procedure should be adequate reduction of stenosis with subsequent
restoration of blood flow. Clot removal is a sine qua non, but the presence of small
amounts of residual thrombus seems to be insignificant because they are likely to be
cleared by the bloodstream.
Each device appeared to be relatively safe to use in our experience although the number
of procedures per device was relatively small. Major complications were rarely encoun-
tered with no clear relation to type of device. In only one of our group of 68 cases, there
were clinical signs of pulmonary embolism, which was confirmed with scintigraphy. The
number of minor complications was relatively high, however, occurring in 31% to 56%
of the cases and comparable for each device group. There were four patients (6%) in
whom asymptomatic arterial embolism was identified, the first of whom was treated
with intra-arterial infusion of urokinase. The following three patients with asympto-
matic arterial embolism were not treated and none developed late sequelae. Distal arteri-
al mapping was not routinely performed and, thus, the true incidence of arterial
embolism may have been higher. It is well recognized that, in many instances, pulmonary
or arterial embolism occurs after mechanical thrombolysis without becoming clinically
evident. In a previous study it was shown that in 35% of patients who had undergone the
procedure, there was scintigraphic evidence of new pulmonary emboli, although almost
all of these patients were asymptomatic [23]. In another series of patients who under-
went surgical thrombectomy, arterial embolization was found in eight (12%) of cases. In
only one of the eight cases was the condition symptomatic [24]. Thus, the risk of
embolism of the clot fragments is a potential complication of the procedure no matter
what thrombolysis treatment is used. Fortunately, the clinical implications are limited
[25,26].
A limitation of our study is that we did not randomize the application of the three
devices throughout the patient population. Each device was used at a different period of
time, according to its availability during the course of the study. Another shortcoming is
that the type of graft changed during the course of the study as the surgeons who created
the grafts changed their primary choice of graft material from homologous vein to PTFE.
This lead to an unbalanced distribution of graft types among the various treatment
groups. However, in the calculation of success, we used type of graft as one of the param-
eters in the multivariate analysis and found that graft type did not affect the results.
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In conclusion, in our evaluation of three mechanical devices used to declot thrombosed
hemodialysis access grafts, we found that the success of mechanical thrombolysis was
determined more by the success of PTA of underlying stenoses than by the results of clot
removal. The rotating devices performed significantly better than the Hydrolyser in
removing thrombus from hemodialysis access grafts. The effectiveness of the two rotat-
ing devices was comparable.
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Abstract
Background. Double-lumen (DL) catheters are advised as temporary vascular access in
hemodialysis. No data are available indicating that urea reduction ratios (URR) using DL
are better than when using single-lumen (SL) catheters. Aim of the present study was to
compare URR obtained using SL and DL catheters.
Methods. Patients, who needed a temporary access, were prospectively randomized to
have a SL or DL catheter, either in the femoral vein (FV) or in a central vein (CV). With
DL catheters blood flow was targeted on 200 mL/min and with SL on 300 mL/min (150
mL/min effectively). URR was calculated using the formula 1 minus urea post-
dialysis/urea pre-dialysis.
Results. 118 catheters were placed in 81 patients, 33 SL catheters and 28 DL catheters in a
FV, and 30 SL catheters and 27 DL catheters in a CV. During 4 hour dialysis the percent-
age of dialysis sessions providing a URR ≥ 65 % was greater using DL catheters (FV: 25%
versus 4%, CV: 29% versus 11%, both P < 0.05). During 3 hour dialysis differences were
not significant. After increasing flow in DL catheters to 300 mL/min URR improved in
CV and FV with 0.08 ± 0.01 and 0.08 ± 0.02.
Conclusion. Many dialysis treatments using catheters do not result in a URR ≥ 65%. DL
catheters in CV position were most likely to obtain an URR ≥ 65%.
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Introduction
Catheters are widely used for temporary vascular access in hemodialysis patients [1]. Two
types of catheters are available: the single-lumen (SL) catheter and the double-lumen
(DL) catheter. The Vascular Access Committee of the NKF-K/DOQI recommends the DL
catheter for temporary vascular access [2]. Originally, the DL catheter was designed to
alleviate the need for a double-pump system required for SL catheter dialysis. Presently,
most dialysis machines are equipped with a double-pump for SL dialysis. From a theoret-
ical point of view, it is reasonable to assume that dialysis using DL catheters offer a more
effective treatment, because higher effective blood flows can be achieved. However, data
substantiating this assumption are lacking. Therefore, we designed a prospective ran-
domized study comparing SL and DL catheters in terms of adequacy of dialysis and over-
all performance.
Methods
The present study was done in a university hospital based dialysis department and a free
standing dialysis center, in which approximately 150 hemodialysis patients are treated.
All patients requiring temporary venous catheters for vascular access for intermittent
hemodialysis during a certain 6 months period could be included. The Ethical
Committee of the University Medical Center Utrecht approved the trial protocol.
Informed consent was obtained from all participating patients. Catheters placed for
plasmapheresis or for dialysis treatment on the ICU were excluded.
Materials and Study design
Indications for catheter insertion were graft or AV fistula thrombosis, need for dialysis
before the AV fistula matured or before the graft could be punctured, or the need for
acute dialysis without other means of vascular access. Patients were prospectively ran-
domized to either insertion of a SL catheter or a DL catheter.
The standard dialysis prescription included a pump flow of 200 mL/min for DL catheters
and 300 mL/min (150 mL/min effectively) for SL catheter. These flows were chosen
because it was our clinical experience that in the majority of dialysis sessions these flows
can indeed be obtained without too many inflow problems and alarms of the dialysis
machine.
Dialysis efficacy was quantified as the urea reduction ratio (URR). The formula for URR is
1 minus urea post-dialysis/urea pre-dialysis. A blood sample was taken out of the extra-
corporeal circuit at the beginning of the dialysis (urea pre-dialysis). After dialysis a blood
sample was drawn after approximately 20 minutes after stopping the dialysis (urea post-
dialysis) [1]. Blood was analyzed by the hospital laboratory using standard procedures.
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The processed blood volume as indicated by the dialysis machine was also monitored. In
all cases Gambro AK 100 or 200 devices were used.
Variables for over all performance were infection, removal for poor flow or inability to
obtain any flow, bleeding and dislocation.
Catheters: insertion, maintenance and removal
The catheters were inserted either in the internal jugular vein, the subclavian vein or the
femoral vein. The attending physician performing the catheter placement was responsi-
ble for the choice of location. The catheter placement was done on the dialysis ward
under sterile conditions. If necessary, ultrasound equipment was used for localizing the
vein. In the case of subclavian or internal jugular vein canulation, a chest X-ray was made
afterwards to assure the right positioning of the catheter tip. We used the following
catheters: Quinton DL 19.5 cm and Vascath SL 20.0 cm for the femoral and subclavian
vein, the Arrow DL 13.0 cm and Medcomp SL 15.0 cm for the jugular vein.
Catheter maintenance included inspection and cleaning with povidone iodine ointment
of the exit side before each dialysis session and coverage with dry gauze afterwards. After
dialysis catheters were filled with pure heparin.
Catheters were removed if: 1) the catheter was no longer needed; 2) a major complication
occurred, e.g. a bleeding, high suspicion of catheter related infection (fever and/or red-
ness around exit site); 3) catheter occlusion or dysfunction. Femoral vein catheters were
removed after approximately one week according to the NKF-K/DOQI recommenda-
tions [1].
Statistical analysis
Proportions were compared using the χ2 test using Yates’ correction. URR comparison
tests were conducted using two-way ANOVA with the Student-Newman-Keuls method.
Target blood volumes were compared with a t-test using the Mann-Whitney Rank Sum
test. Survival analysis to calculate complication-free survival in central vein catheters was
performed with log rank analysis. A P-value of less than 0.05 was considered significant.
Results
Randomization was done for 118 catheters in 81 patients. 33 SL catheters and 28 DL
catheters were placed in a femoral vein (FV), and 30 SL catheters and 27 DL catheters
were placed in a central vein (CV). In the vast majority of cases the internal jugular vein
was used as central vein. Results of subclavian and jugular vein catheters are presented as
one group. A total of 647 dialyses were done on these catheters resulting in 1338 catheter
days, 723 days for SL and 615 for DL. URR was obtained from 478 dialyses, 246 from SL
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catheter dialysis and 232 from DL catheter dialysis.
The Table shows URR for 3-hour and 4-hour dialysis. Use of CV catheters for dialysis
resulted in a higher URR than FV catheters (P < 0.01), except for the 3 h SL dialysis.
During 4-hour dialysis URR using DL catheters was greater than using SL catheters,
whereas this was not the case for 3-hour dialysis sessions. For a given location and
catheter type, URR during 4-hour dialysis was significantly better (P < 0.05) than that of
3-hour dialysis, except for the SL FV catheter dialysis (P = 0.083). DL catheters were
more likely to process the target volume of blood than SL catheters (Table). Only 5.7% of
the SL and 9.2% of the DL dialyses resulted in an URR of ≥ 65%.
FV catheters remained in place for approximately one week (SL 7.7 ± 5.6 and DL 6.3 ±
4.5 days, respectively 3.2 ± 1.9 and 2.7 ± 1.7 dialysis sessions) and the CV catheters were
present for approximately 25 days (SL 25.5 ± 13.7 and DL 25.5 ± 10.1 days, respectively
7.7 ± 4.7 and 8.1 ± 6.4 dialysis sessions). The majority of the catheters was removed,
because they were no longer needed. Other reasons were thrombosis, bleeding, disloca-
tion, (suspected) infection, and a group with other reasons such as death, or lost to fol-
low-up. There were no statistical differences in reasons for removal between both types
of catheters.
Catheter survival curves (Kaplan-Meier analysis) with an event defined as one of the
complications (i.e. thrombosis, bleeding, dislocation, or (suspected) infection) were not
different (P = 0.13).
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Table 1. Urea reduction ratio for 3- and 4-hour dialysis and achieved percentage of target
blood volume and percentage (between brackets) of dialysis sessions reaching URR of
≥ 65%.
SL n DL n P
URR 3h FV 0.46 ± 0.15 (6%) 32 0.45 ± 0.13 (4%) 26 NS
URR 3h CV 0.50 ± 0.10 (5%) 84 0.51 ± 0.07 (1%) 100 NS
P NS < 0.001
URR 4h FV 0.47 ± 0.13 (4%) 46 0.52 ± 0.11 (25%) 26 0.030
URR 4h CV 0.55 ± 0.09 (11%) 84 0.58 ± 0.09 (29%) 80 0.041
P < 0.001 0.006
% target vol. FV 87 ± 14 95 ± 9 < 0.001
% target vol. CV 92 ± 11 95 ± 15 < 0.001
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Finally, we tested the option that increasing the flow in the DL catheters from 200 to 300
mL/min would result in improvement of URR. In 25 cases (16 central vein and 9 femoral
vein) paired observations were made within the same patient with dialysis time
unchanged. URR increased with 0.08 ± 0.01 in CV catheters and with 0.08 ± 0.02 in FV
catheters. In 28% (7/25) of the patients (4 central vein and 3 femoral vein catheters) were
unable to obtain 300 mL/min and one case (central vein) could not even reach the 200
mL/min when the target was 300 mL/min.
Discussion
To our knowledge this is the first study comparing in a prospective randomized trial dial-
ysis adequacy obtained using DL and SL catheters for temporary use. This study allows a
number of clinically relevant conclusions. In vast majority of cases the URR of 0.65, rec-
ommended by the NKF-K/DOQI Committee as indication for adequate dialysis, was not
obtained using either the SL or DL catheters [1]. Dialysis using catheters in CV position
is more effective than catheters in FV position. During 4 h of dialysis DL catheters pro-
vide a higher URR than SL catheters. Although some comparisons were statistically sig-
nificant favoring the use of DL catheters, differences were clinically not very impressive.
Overall performance did not differ.
During the use of temporary catheters an important obstacle in the effort to achieve an
adequate URR is the inability to obtain the prescribed flow and recirculation of
processed blood. In the present study DL catheters were more likely to process the pre-
scribed blood volume than SL catheters. Furthermore with DL catheters, in present set-
tings of the dialysis machines, the processed volume of blood was one third greater than
SL catheters. During 4 hours of dialysis this resulted in a higher URR. Although statisti-
cally significant, the obtained differences were not very great. The clinical relevance is
difficult to establish, but likely to be limited.
We confirm earlier data that adequacy of FV catheters is lower than that of CV catheters
[3]. This is probably due to an anatomic factor. Blood flow in the central vein close to the
right atrium is higher than in the iliac vein or inferior caval vein, resulting in a lower
probability of recirculation.
Adequacy of DL catheters can be improved by increasing blood flow of the dialysis
machine. Especially in femoral catheters, this may be associated with an increase in recir-
culation, partially off setting the beneficial effect [4]. However, in the present study URR
increased with approximately 15% in both CV and FV catheters.
Several limitations of this study need to be discussed. We tested a limited number of
catheters only. We can not exclude the possibility that other types would result in other
results. Especially longer catheters (25 cm) in the FV position are likely to produce more
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effective dialysis than the 19.5 cm catheter we used. We also did not explore the possibili-
ty that increasing flow in SL catheters or prolonging the dialysis time would be of benefit.
The present settings and dialysis time were a compromise between the number of alarms
by the dialysis machine (with respect to flow) and the acceptability of dialysis treatment
by the patient (time).
What may be the implications of the present study for the every day clinical practice? The
present study shows that many dialysis sessions, using the present setting of dialysis
machines, do not meet the standards suggested by the NKF-K/DOQI Work Group.
Dialysis sessions using DL catheters in CV position were most likely to reach the stan-
dard. URR could be further improved by increasing flow. In 25% of cases it was not pos-
sible to obtain a flow of 300 mL/min. Whether the inability to reach an URR ≥ 65% is of
any clinical relevance, when it only concerns a limited number of treatments is question-
able. The present data do not support the conclusion that DL catheters, processing blood
at 200 mL/min, provide a much more effective treatment than SL catheters. Especially
when short-term (arbitrarily defined as some days to one or two weeks) use is expected,
it seems unlikely that adequacy differences will be of any relevance. In such cases one
may conclude that SL catheters are preferable. DL catheters should then be reserved
when longer duration is expected (up to several weeks), which in the case of femoral vein
location would mean repeated cannulation. In addition, it is conceivable that SL
catheters cause less vascular damage, resulting in less risk for stenosis. We were unable to
find studies addressing the issue. Finally, SL catheters are much cheaper, although dialysis
lines necessary for SL catheter dialysis are more expensive than those used with DL
catheters. Therefore, especially when only a limited number of dialysis sessions are antic-
ipated, the use of SL catheters might turn out to be cheaper. Taken these considerations
together it seems that SL catheters are, at least in selected cases, an acceptable alternative
to DL catheters in providing a temporary vascular access.
In conclusion, the present study shows that using DL catheters often results in better
URR. Differences obtained with SL catheters are limited and, especially when only a lim-
ited number of dialysis sessions are performed using catheters, of questionable clinical
relevance.
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Introduction
An increased thrombotic tendency is an important cause of complications in patients on
chronic hemodialysis leading not only to possibly fatal complications like ischaemic
heart disease, or stroke, but also to thrombosis of the vascular access [1]. This latter com-
plication remains the main problem in vascular access for haemodialysis, particularly in
polytetrafluoroethylene (PTFE) grafts. It accounts for considerable morbidity and mor-
tality with an estimated annual cost of close to $1 billion in the United States. Moreover,
vascular access complications mainly consisting of thrombotic events are responsible for
17 - 25% of all hospitalizations in dialysis patients [2-4].
In most cases thrombosis is associated with low access blood flow [5-7]. The most
important reason for a decreasing access blood flow is intimal hyperplasia formation at
the venous anastomosis or in the outflow tract of the graft [8-13]. However, not all
decreases in access blood flow are related to intimal hyperplasia or stenosis formation.
Other causes for low access flow leading to access thrombosis have been proposed (Table
1). Hypotension, hypovolaemia, or external compression may be involved in these non-
stenotic thrombotic events [14]. Also, there has been a growing appreciation of the role
of increased hypercoagulability found in these patients.
This review will discuss coagulability abnormalities in relation to haemodialysis access
thrombosis. First, an outline will be given regarding normal haemostatic and fibrinolytic
responses. Subsequently, we will focus on coagulation abnormalities leading to the
thrombotic tendency in chronic haemodialysis patients. And finally, preventative meas-
ures for these coagulation defects will be discussed.
Normal haemostasis and fibrinolysis
Normal haemostatic responses are initiated by damage of the vessel wall with exposure of
subendothelial structures to flowing blood and results in the formation of a solid haemo-
static plug. The first step of this haemostatic response involves platelet adherence to the
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Table 1. Possible causes of vascular access thrombosis 
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subendothelium [15-17]. The number of platelets available for this process is determined
by platelet count. It is however, even more dependent on red blood cell-mediated trans-
port of circulating platelets towards the vessel wall [17-19]. The adhesion of platelets to
the site of injury is initially mediated by interactions between specific platelet receptors
(e.g. glycoprotein Ib) and adhesive proteins in or deposited on the subendothelium (e.g.
von Willebrand factor, vWF) [20-22]. The quality of the platelet adhesion, however,
depends strongly on subsequent platelet activation. Platelet activation is initiated by
stimuli originating from the vessel wall but is sustained by products released from acti-
vated platelets themselves, for example thromboxane and adenosine diphosphate (ADP)
[22]. Platelet activation leads to expression of additional receptors on platelet mem-
branes which support platelet interaction with subendothelium (e.g. glycoprotein
IIb/IIIa) [22-25]. Most importantly, however, these receptors mediate platelet-platelet
interactions resulting in aggregate formation.
Normal haemostasis also involves initiation of coagulation at sites of vessel wall injury
that starts with activation of factor VII from flowing blood by tissue factor present in the
vessel wall. The key products of the coagulation cascade are thrombin and fibrinogen.
Thrombin proteolytically converts fibrinogen to insoluble fibrin, which in its turn acti-
vates factor XIII that causes cross-linking of fibrin fibres [26]. With collagen, thrombin is
also a main stimulus of platelet activation and aggregation [22]. Fibrin is able to stabilize
platelet aggregates and other cellular elements in a shear stress resistant network.
Pathological thrombin formation is prevented by natural anticoagulant systems, of which
antithrombin III and the vitamin K-dependent protein C systems are the most important
ones. In addition to these anticoagulant systems the fibrinolytic system generates plasmin
by the action of tissue plasminogen activator on plasminogen. Plasmin dissolves the fibrin
clot and thereby prevents pathological thrombus formation. Thus, normal haemostatic
responses require both coagulation and platelet-dependent processes.
In haemodialysis patients complex coagulation abnormalities occur ranging from bleed-
ing to thrombosis [1,27]. On the one hand, the enhanced bleeding tendency in these
patients is primarily based on functional platelet abnormalities and defective adhesion to
the vessel wall [28,29]. On the other hand, a variety of coagulation abnormalities con-
tribute to an increased thrombotic tendency.
Factors in chronic haemodialysis patients contributing to
thrombotic tendency
Hypercoagulability in patients on chronic haemodialysis can be caused by a variety of
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Platelet abnormalities
Platelet abnormalities are common in patients on haemodialysis. Paradoxically, most
studies on platelet abnormalities in haemodialysis patients have focused on adhesion
defects leading to an increased bleeding tendency. So, first of all, do these platelets actual-
ly play a role in the thrombotic tendency seen in patients on haemodialysis? In other
words, are there abnormal circumstances leading to an increase of thromboembolic
complications in a setting of dysfunctional platelets? Indeed, there are indications that
this is the case. Although these platelet abnormalities exist which favour a bleeding ten-
dency, other circumstances may actually lead to an increase in thrombotic complications.
First of all, although some studies suggest a decreased membrane expression or an
abnormal activation of platelet receptors (glycoprotein Ib and IIb/IIIa) [30,31], an
increase in platelet receptor number may be related to frequent access obstruction [32].
Also, haemodialysis is thought to activate platelets by adherence to the extracorporeal
circuit [33,34]. In addition to extracorporeal activation, high shear stress and turbulence
in the vascular access may be responsible for further platelet activation [35,36]. Another
condition favouring vascular access clotting is that the artificial surface of the PTFE graft,
and to a lesser extent the native arteriovenous (AV) fistula, promotes the adhesion of fib-
rinogen [37,38]. Serum fibrinogen, which is increased in haemodialysis patients, adheres
to glycoprotein IIb/IIIa on the surface of the platelet. Once attached to the surface (solid
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Table 2. Factors contributing to an increased thrombotic tendency in patients on chronic
haemodialysis
Platelet factors
-blood - artificial surface interaction
-treatment with recombinant human erythropoetin
-increased platelet count
-platelet activation due to high shear stress in the vascular access
Plasma factor abnormalities
-increased levels of vWF
-hyperfibrinogenaemia
-increased thrombin formation
-reduced levels of protein C anticoagulant activity
-high levels of factor VIII procoagulant
-decreased levels and reduced activity of antithrombin III
-impaired release of plasminogen activator
-increased levels of antiphospholipid antibodies 
-increased levels of homocysteine
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phase fibrinogen) it can also bind to inactivated platelets, thereby activate them, and fur-
ther enhance platelet deposition on the surface [37]. Indeed, Windus et al. [39] have
shown that platelets are deposited along the vascular access surface. Another possible
complementary explanation could be that clotting factor (contact factors like factor XII)
deposition may lead to local thrombin formation, platelet activation, and enhanced
platelet deposition [40].
Adherent platelets may release factors (platelet-derived growth factor (PDGF), for exam-
ple) which lead to or enhance intimal hyperplasia in the vascular access and thereby
reduce blood flow through the access, which allows other activated or non-activated
platelets to aggregate more easily. This creates, despite a bleeding tendency, a favourable
situation for thrombosis.
Plasma factor abnormalities
Uraemic subjects have higher levels of fibrinogen while at the same time thrombin for-
mation is increased [41,42]. Song et al. [43] showed that a high plasma fibrinogen level is
an independent risk factor for vascular access failure in haemodialysis patients. In addi-
tion, levels of antithrombin III may be decreased and antithrombin III activity may be
reduced [44,45]. The subsequent increase of in vivo fibrinogen-fibrin transformation is
reflected by increased fibrinopeptide A formation.
Erdem et al. [46] also provided evidence for a substantial contribution of the vascular
access itself to the modulation of the thrombotic tendency. By taking blood samples from
the vascular access and from contralateral large veins in end-stage renal disease (ESRD)
patients and from peripheral veins in control subjects, they showed not only a difference
in parameters of thrombotic tendency between peripheral vein samples in ESRD patients
and controls, but more importantly, also between vascular access samples and peripheral
vein samples in the same ESRD patient group.
Others have shown that in antiphospholipid antibodies are predictive of vascular access
thrombosis [45,47-49]. These antibodies include lupus anticoagulant (LA), anticardi-
olipin antibodies (ACA), and antiphosphatidyl serine antibodies. Higher titres of both
ACA and LA antibodies have been demonstrated in patients with ESRD than in the gen-
eral population [48,50,51]. Elevated LA antibody titres are present in up to one-third of
haemodialysis patients [48]. Elevated ACA antibody titres have been found in 0 - 29% of
them [48,52,53], with a greater prevalence in patients with AV grafts (22%) than with
native AV fistulae (6%) [47]. However, the association between elevated ACA antibody
titre and increased access thrombosis is not fully established yet. While several studies
found no association [48,52,54], Prakash et al. [47] demonstrated in a retrospective
study a 3.7 times increased risk of recurrent thrombosis in patients with PTFE grafts hav-
ing elevated ACA antibody titres. The latter finding was recently confirmed in a prospec-
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tive study: the survival time of PTFE grafts in patients with elevated titres was signifi-
cantly shorter than in patients with normal titres. Interestingly, this difference was not
found in patients with native AV fistula [53].
Hyperhomocysteinaemia is an independent risk factor for recurrent and early-onset
venous thrombosis in patients with normal renal function [55-57]. Fasting homocysteine
levels have been shown to be elevated in patients with ESRD [58] and may contribute to
atherosclerosis and subsequent cardiovascular events in haemodialysis patients [59,60].
The underlying mechanism by which hyperhomocysteinaemia provokes thrombosis is
uncertain. It may involve a change in factor V and protein C complex activity as well as
effects on platelet function [56,61,62].
Studies on the association of homocysteine and access thrombosis are limited and the
results are controversial. In a retrospective study by Manns et al. [52] no association
between homocysteine level and access thrombosis was found. Two recent prospective
studies showed conflicting results. Shemin et al. [63] demonstrated a 4% increase in the
risk of access thrombosis with each 1 µmol/l increase of plasma homocysteine concentra-
tion for both AV fistulae and grafts. Similarly, Ducloux et al. [64] suggested that hyper-
homocysteinaemia is a risk factor for vascular access thrombosis. However, such an
association could not be demonstrated in a population of 96 patients with only native AV
fistulae. The patients with the lowest levels even appeared to have an increased mortality
risk [65]. These conflicting differences in outcome may be related to the type of fistula, to
the length of follow-up, and to other variables. Obviously, long-term prospective studies




The usefulness of antiplatelet therapy for the maintenance of internal haemodialysis
access devices was reviewed by the Antiplatelet Trialists’ Collaboration Group [66].
Outcomes of nine placebo-controlled randomized trials showed an occlusion rate of
17% in the antiplatelet groups vs 39% in the control groups. Antiplatelet regimens con-
sisted of ticlopidine (five studies), aspirin (two studies), and sulphinpyrazone (two stud-
ies). Unfortunately, most of the evaluated studies were conducted in the late 1970s and
the beginning of the 1980s. At that time some of the achievements in modern dialysis
were not yet available, and dialysis populations differed from those of today. Moreover,
these studies had only a short follow-up (mean 2 months). Finally, the analysis report
was difficult to interpret in terms of excess bleeding due to antiplatelet therapy.
Only one randomized, placebo-controlled clinical trial comparing access thrombosis fre-
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quency in patients treated with antiplatelet therapy (dipyridamole 75 mg orally 3 times a
day, or aspirin 325 mg orally daily) was conducted in the last decade. Surprisingly, dipyri-
damole alone, which is considered a relatively weak platelet inhibitor, had the best out-
come, while patients on aspirin had the highest frequency of thrombosis, even higher
than with placebo or the combination of dipyridamole and aspirin [67]. The results of
this study became more understandable after the authors conducted a series of in vitro
experiments using vascular smooth muscle cells [68,69]. They could show that aspirin
potentiated PDGF-induced vascular smooth-muscle cell proliferation by shunting
arachidonic acid from cyclo-oxygenase into lipoxygenase pathways. On the other hand,
dipyridamole profoundly inhibited PDGF- and bFGF-induced vascular smooth-muscle
cell proliferation. This suggests that the observed direct effect of aspirin and dipyri-
damole on vascular smooth-muscle cell proliferation (rather than the antiplatelet effect)
is a better explanation for the reported clinical efficiency of dipyridamole.
Gastrointestinal bleeding occurred in 16% of the treated patients vs 8% in the placebo
group. Unfortunately, no anatomical data or functional data (e.g. vascular access flow)
was collected in the randomized trial [67]. This could have provided further in vivo evi-
dence for the experimental in vitro data.
Finally, Windus et al. [70] showed that aspirin and ticlopidine both reduced dialysis-
associated platelet deposition in PTFE grafts, although they did not completely prevent
it.
Oral anticoagulation
Current opinions on the use of systemic anticoagulant therapy to improve access patency
is primarily based on personal belief rather than on evidence. Not surprisingly, the rea-
son is that systematic data on this subject are very limited. Interestingly, despite the lack
of consensus nephrologists do not refrain from prescribing anticoagulants. As a conse-
quence numerous different anticoagulant strategies exist from centre to centre as to
patient selection, dosing scheme, and treatment duration.
In 1967, the effect of coumadin in reducing the clotting frequency of AV Scribner shunts
was first reported in three dialysis patients [71]. A few years later coumadin was shown to
prolong cannula shunt life in non-uraemic sheep [72]. However, in several recent studies
aimed at evaluating risk factors for vascular access dysfunction, anticoagulants were
either not used in the study population or their use was not mentioned. Nevertheless, the
use of anticoagulants was advocated based on the hypercoagulable state often found in
the dialysis patients under study [48,73]. In a recent Japanese study in 83 dialysis patients
with AV fistula dysfunction, no association was found with prior anticoagulant use or
prothrombin time [74]. However, the criteria mentioned for fistula dysfunction were
vague and the distribution of various access types (AV fistula or PTFE) in this population
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was not mentioned. Dialysis patients with a history of early vascular access graft loss or
frequent thrombosis showed a twofold prolongation of access survival time and less fre-
quent clotting after initiation of coumadin [53,75]. However, these results were based on
small numbers and obtained with patients being their own controls. Bleeding complica-
tions seen in these studies occurred in patients with high international normalized ratio
(INR) levels. Also, LeSar et al. [45] showed in a subgroup of dialysis patients with fre-
quent PTFE graft thrombosis and a hypercoagulable state (i.e. prevalence of antiphos-
pholipid antibodies, anti-thrombin III and protein C system abnormalities), that oral
anticoagulant therapy effectively decreased thrombosis frequency, particularly with INR
values maintained at 2.7 - 3.0. However, the incidence of significant bleeding complica-
tions in this subset of patients was 10% per year. By administering coumadin, Valeri et al.
[53] increased the survival of access grafts in 16 patients with elevated ACA antibody
titres and frequent access thrombosis. However, the absolute duration of graft survival in
the treated group was not impressive (48 ± 12 days in the untreated group vs 103 ± 26
days in the patients on coumadin with target INR values of 2.0 - 3.0). Two patients suf-
fered major bleeding complications, although both had an overshoot of target INR (> 8).
Conclusion
Despite the bleeding tendency of chronic haemodialysis patients, vascular access throm-
bosis is a frequent complication. Hypercoagulability is one of the causes contributing to
the high frequency of access thrombosis. The hypercoagulable state can be explained by
platelet and coagulation factor abnormalities. Unfortunately, few randomized placebo-
controlled trials were conducted using antiplatelet or oral anticoagulation therapy.
Therefore, no evidence-based consensus has been established regarding pharmacological
prevention of access thrombosis. It still needs to be determined whether the potential
benefits of anticoagulation and antiplatelet therapy outweigh the risk of adverse events.
In the meantime it seems reasonable to give some form of anticoagulant therapy based
on pathophysiological considerations and the high incidence of thrombotic complica-
tions. Our group recently demonstrated that graft flow measurements could effectively
predict thrombotic vascular access events [76]. Risk tables that take into account such
parameters as well as plasma markers of hypercoagulability may help to develop rational-
ly designed trials and guidelines.
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General discussion
Nowadays, hemodialysis offers an important treatment modality for patients with end-
stage renal disease (ESRD). Many problems with hemodialysis technique and equipment
have been dealt with. With hemodialysis, ESRD patients can survive for many years.
However, patients on hemodialysis require an access to their bloodstream three times a
week. Because of its low infection and thrombosis rate, the Brescia-Cimino (radio-
cephalic) fistula is still regarded as the first choice for the creation of a vascular access for
hemodialysis [1]. Unfortunately, not all patients have suitable vessels to construct an AV
fistula, mainly because of their insufficient caliber or sclerosis due to prior venipunc-
tures. Due to ageing of the dialysis population and prolongation of the dialysis therapy,
more and more secondary accesses are used. These secondary accesses can consist of
intravenous catheters or, more commonly, a modification of the AV fistula: an interposi-
tion graft between an artery and a vein. The interposition AV graft functions as a vascular
access by itself. Nowadays, AV grafts are predominantly manufactured from expanded
polytetrafluoroethylene (PTFE).
Unfortunately, these PTFE AV grafts show a thrombosis rate of 0.5 - 2.5 per patient-year
[1-5] resulting in considerable morbidity and even mortality [6,7]. For the United States,
it was calculated that vascular access morbidity is responsible for an estimated annual
cost of close to $1 billion and accounts for 17 - 25% of all dialysis patients hospitaliza-
tions [8-11]. Because of these complications the NKF-K/DOQI guidelines on vascular
access suggest that vascular access using AV grafts may only be considered, if it is not pos-
sible to establish either a radio-cephalic or a brachio-cephalic AV fistula [1,12]. Despite
the higher rate of thrombosis and its subsequent morbidity, an increasing number of
patients depend on an AV graft. In some populations in the United States, AV grafts
account for as many as 83% of access placements [13]. Because of the increasing age of
the hemodialysis patients, establishment of an AV fistula in those patients becomes diffi-
cult due to insufficient vessels. Also, the number of patients with end-stage renal disease
(ESRD) requiring hemodialysis is increasing worldwide [14]. In The Netherlands the use
of AV grafts is increasing at the expense of AV fistulae [15]. As a consequence, patients
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Vascular access surveillance
In most cases thrombosis is associated with the presence of stenoses at the venous anas-
tomosis or in the outflow tract [16-20]. Stenosis increases resistance over the flow tract.
Because the graft has no autoregulating capacities, blood flow (Qa) drops and venous
pressures (VP) rise. These variables have been shown to predict thrombosis. More
importantly, several studies demonstrated that referral for corrective intervention based
on these parameters can prevent thrombosis [21-25].
Patients with outflow stenosis have on average a higher VP and/or lower Qa [21,26].
However, VP does not correlate with Qa. In other words not all patients with high VP
had low Qa, indicating that not all patients who are at risk for thrombosis can be identi-
fied by VP measurements. It is also shown that inflow resistance (that is resistance of the
flow tract upstream of the venous needle) comprises a substantial and very variable part
of total graft resistance. Indeed, several studies have indicated that in up to 29% of
thrombosis cases, stenoses may be located in the arterial part of the graft [20,27-30]. The
inflow resistance is not reflected by VP measurements, whereas Qa measurements are a
reflection of total graft resistance. This could make VP less effective as selection parame-
ter for patients at risk for thrombosis than Qa. In contrast to Qa measurements, VP can
be measured by the dialysis machine, is easy to obtain and requires little time investment.
Furthermore, some studies have convincingly indicated that the use of VP measurements
as a selection variable for diagnostic and subsequent corrective procedures, results in
thrombosis rates between 0.2 and 0.4 events per patient-year [3,21,23]. Although the the-
oretical basis was provided that Qa measurements are better than VP measurements, the
question is whether Qa measurements really confer additional benefit in patients who are
monitored by VP. In other words, when simple clinical variables such as VP are used, is
there any additional benefit when periodic Qa measurements are added to the surveil-
lance protocol?
We addressed these questions in chapter 3 with the following hypotheses: Qa measure-
ments are better than VP measurements in identifying patients at risk for thrombosis. As
a consequence, referral of patients for corrective interventions based on Qa measure-
ments alone or on the combination of VP and Qa reduces thrombosis rate more than
referral based on VP alone.
We found that thrombosis rates in patients monitored and selected for corrective inter-
ventions based on VP or Qa can be maintained below the quality of care standards for-
mulated by the NKF-DOQI committee [1]. Secondly, we showed that thrombosis rates in
groups monitored by VP or Qa alone or by the combination of tests do not differ.
Thirdly, only a small minority of patients was selected for corrective interventions by Qa
alone in the group with combined monitoring of VP and Qa. Fourthly, after obtaining
abnormal tests subsequent diagnostic and interventional procedures should be instituted
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on short notice. It seems likely that the number of thromboses during the waiting time
can be reduced. Finally, we confirmed that static VP is more effective than dynamic VP
for monitoring dialysis grafts.
What may be the implications of the present study for everyday clinical practice? We
showed that using the surveillance protocol of this study outcome with respect to throm-
bosis rate is equal in Qa monitored grafts and in VP monitored grafts and that there is no
rationale in combining the two methods. Each dialysis center should decide which
method is best suitable for their dialysis practice. VP measurements are easy to obtain
and require little time investment. However, they need discipline. Qa measurements are
more time consuming and a special device is needed. We showed that by measuring Qa
every 4 to 8 weeks identical results can be obtained as with weekly VP assessments. The
decision which method to use, will be primarily based on the preferences of those
involved in the access care and on the possibilities to implement a certain surveillance
strategy.
So, we have demonstrated that standardized monitoring of VP or Qa or the combination
of both and subsequent corrective intervention can decrease thrombosis rates to below
0.5 per patient-year, which is recommended by the Vascular Access Task Force of the
NKF-DOQI Committee as quality of care standard [1]. When applying our study proto-
col, VP, Qa, or the combination as variables for selection of patients for corrective inter-
vention are equally effective in reducing thrombosis rates in hemodialysis access grafts.
Access imaging
To treat a failing access (either by percutaneous transluminal angioplasty (PTA) or by
surgical intervention [1]), it is necessary to identify the underlying problem, i.e. in most
cases one or more stenoses, predominantly found at the anastomosis of an AVF and at
the venous anastomosis of an AVG [17-20,31]. The conventional technique to identify
and locate stenosis has predominantly been digital subtraction angiography (DSA).
However, there are several drawbacks: the radiation load for the patient and radiology
personnel, the use of potentially nephrotoxic iodinated contrast agents, and limited spa-
tial information [32]. Magnetic resonance angiography (MRA) does not have these dis-
advantages and could offer an attractive alternative. In addition, MRA offers the
possibility to measure access flow. Access flow has been shown to be a better parameter
for impending vascular access failure than anatomical information alone [5,25,33].
However, a major problem with flow-based approaches to MRA, such as phase-contrast
(PC) and time-of-flight (TOF), has always been the frequent occurrence of flow artifacts
in regions with disturbed flow that complicate interpretation of the MR angiograms.
Especially near stenoses (but also near bends and cusps [34]), the appearance of the
lumen is distorted by a combination of dephasing, displacement and, for TOF methods,
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saturation artifacts [35]. Application of PC and TOF to hemodialysis accesses, i.e. both
AVF and AVG, also suffers from the above types of inaccuracies [36,37], but interpreta-
tion of the angiograms is further complicated by the large range of flow rates that occurs
in these vessels: roughly 100 - 3000 ml/min. As flow disturbances tend to increase with
flow rate, signal voids may easily arise at mild narrowings or sharp-angled anastomoses,
when a high flow rate is present [38].
Contrast-enhanced (CE) MR angiography is less sensitive to these artifacts [39], and has
been reported to improve hemodialysis access visualization, when compared to TOF and
PC [40]. However, flow related artifacts remain present under the extreme flow condi-
tions that occur in hemodialysis accesses [41]. To eliminate these artifacts, we borrow
from the procedure used for DSA of the hemodialysis access, and use a cuff to obstruct
the blood flow temporarily [42,43]. In chapter 4 we validated this novel MRA technique
anatomically, and for this purpose we compared anastomotic (AVG) and post-anasto-
motic diameters (AVF) of MRA images obtained with flow-interruption and selective
contrast administration with those diameters scored on conventional DSA imaging of
hemodialysis accesses.
We showed that selective flow-interrupted CE-MRA imaging is able to provide excellent
quality images of hemodialysis AVF and AVG, which are free of flow artifacts. The high
image quality of the MR angiograms is comparable with DSA. In combination with MR
flow quantification and imaging of the outflow tract, our approach may provide a com-
plete anatomical and functional evaluation of hemodialysis accesses on MR.
Access function after PTA
Routine surveillance programs for the early detection of stenoses followed by angioplasty
have been shown to substantially reduce the number of thromboses per patient year
[19,21,23,44]. However, repetitive PTA treatment is often necessary, since re-stenosis fre-
quently occurs. Although the short term success rates of PTA range from 85% to 98%
[45], patency at 6 months follow-up varies from 38% to 63% [17,22,23,46].
Several studies have shown that angiographic degree of the stenotic lesion before and
after PTA is poorly related with its subsequent patency [17,22,33,47,48]. Recently, the
SCVIR Technology Assessment Committee recommended that PTA efficacy should be
expressed by both angiographic and functional parameters [49]. In particular, access flow
(Qa) measurements offer the opportunity to quantify and follow up the functional effect
of PTA.
In chapter 5 we quantified the short-term functional and angiographic effect of PTA.
Additionally, we determined the longevity of the functional effect during follow-up.
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We demonstrated that angiographic results do not correlate with functional results.
Importantly, we also showed that functional variables are predictive for long-term out-
come, whereas angiographic results are not. The study confirms recent data indicating
that PTA results in a direct increase in Qa of approximately 250 mL/min [50]. We also
confirm that a substantial percentage of PTA is not successful. Finally, time to repeat PTA
in our study is substantially shorter than in other studies [22,50,51]. This suggests a more
rapid recurrence of stenosis in the present study. The combined data of these studies sug-
gest that there is an optimal moment of PTA.
Thrombolysis
Thrombosis of the access graft is an acute problem for the patient on chronic hemodialy-
sis and treatment should be initiated immediately after diagnosing graft thrombosis.
Usually, patients are referred to the vascular surgeon who performs surgical thrombecto-
my, i.e. clot removal with a balloon catheter through a small incision in the graft. When
this procedure is unsuccessful in restoring graft flow, which is often the case, graft revi-
sion is done. Graft revision often means that a new venous anastomosis is created. When
revision of the graft is not possible, a new one is created. A patient has only a limited
number of sites where a graft can be implanted. Therefore, it is of the utmost importance
to preserve functioning access sites as long as possible [17,52]. Percutaneous thromboly-
sis typically tries to keep the local anatomic situation intact.
Therefore, percutaneous thrombolysis has become an accepted treatment of thrombosed
hemodialysis grafts, and in many institutions clotted grafts are primarily referred to the
radiologist [45,52]. The main difference with surgical thrombectomy is that the percuta-
neous techniques visualize the underlying problem, i.e. vascular stenosis. A number of
percutaneous techniques have been reported. In pharmacological thrombolysis a lytic
agent such as streptokinase or urokinase is administered intravenously or directly into
the graft [53,54]. With pulse spray pharmacomechanical thrombolysis, using a dedicated
multi side hole infusion catheter, lysis is accelerated by injecting the lytic agent into the
clot [29,52]. Lysis of the clot can be accelerated even more by maceration of the clot with
a mechanical device. These devices macerate the clot using different mechanical actions
such as aspiration and fragmentation [55-57]. Over twenty devices for mechanical
thrombolysis have been developed. Comparison of the efficacy of these devices is diffi-
cult. Most studies report on a single device only.
In our institution, we gained experience with three mechanical devices for thrombolysis
(chapter 6). The mechanical devices were compared with respect to their efficacy of
removing thrombus from hemodialysis access grafts. The first device was a rotating
brush (Cragg brush catheter) that shreds the clot after which small fragments disperse in
the bloodstream or embolize to the lungs [58]. According to the instructions of the man-
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ufacturer, urokinase is applied to the thrombus before application of the brush to partial-
ly lyse the clot and to facilitate fragmentation and dissolution. When the Cragg brush was
temporarily withdrawn from the market, we started to use the Hydrolyser, a hydrody-
namic catheter [59,60]. The Hydrolyser fragments the thrombus by a high-velocity jet of
saline, after which the clot fragments are suctioned and evacuated. The third device was a
mechanically driven, rotating basket, which macerates the clot (Arrow-Trerotola PTD)
[61]. After maceration of the clot with the PTD, most of the clot fragments are aspirated
with a syringe through the device’s introducer sheath and removed.
Clot removal was achieved in 66 of 67 cases. Clot removal with the rotational, wall con-
tact type devices (i.e. the Cragg brush and the PTD) provided better clot removal than
the Hydrolyser. However, the percent technical success after thrombolysis and the long-
term patency rates did not differ between the different devices. Percutaneous thrombus
treatment consists of two stages. First the clot is removed with the chosen device. When
the graft is cleared of clot material, the underlying cause is visualized and subsequently
treated with percutaneous transluminal angioplasty (PTA).
However, PTA was often unsuccessful, independent of the type of device used. In multi-
variate analysis, the percentage of residual stenosis after PTA was the single factor that
determined long-term patency rates. It was concluded that clot removal was successful in
almost every case independent of what device was used. The wall contact devices provid-
ed better clot removal than the Hydrolyser. The key issue of thrombolysis is the detection
and subsequent correction of the underlying stenosis.
Temporary catheters
Catheters are widely used for temporary vascular access in hemodialysis patients [7].
Basically, two types of catheters are available: the single-lumen (SL) catheter and the
double-lumen (DL) catheter. The Vascular Access Committee of the NKF-K/DOQI rec-
ommends the DL catheter for temporary vascular access [1]. Originally, the DL catheter
was designed to alleviate the need for a double-pump system required for SL catheter
dialysis [62]. Nowadays, most dialysis machines are equipped with a double-pump for SL
dialysis. It has been suggested that SL catheters have several possible advantages over DL
catheters. These include the following overall performance parameters: the smaller diam-
eter resulting in easier insertion, a lower rate of infectious complications [62,63], a better
patency, and less recirculation [64,65]. Also, it has been stated that the use of SL catheters
tends to be cheaper in the short-term, i.e. less than a year [66]. However, to determine
whether there is still a place for the SL catheter in modern dialysis, it is important to
compare its ability to deliver an adequate dialysis dose to that of the DL catheter. In
chapter 7, we describe a prospective randomized study comparing SL and DL catheters
in terms of adequacy of dialysis and overall performance.
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We could not demonstrate a difference in adequacy for the short-term dialysis (3-hour)
between SL versus DL catheters, and only a marginal difference for the longer-term dialy-
sis (4-hour). Overall performance did not differ between SL and DL catheters.
The recommended URR of 0.65 by the NKF-K/DOQI Committee was not reached in
either the SL or DL catheters [1]. A possible explanation for this could be that the chosen
pump flow was not high enough to achieve sufficient URR. On the other hand, in a sub-
set of patients dialyzing on DL catheters we looked at the URR with a dialysis pump flow
of 200 mL/min versus 300 mL/min. Although the URR with a pump flow of 300 mL/min
(0.49 ± 0.09) was higher than with a pump flow of 200 mL/min (0.41 ± 0.10), we also
found that 28% of the patients could not reach this level of 300 mL/min at all. Maybe an
already present recirculation in DL catheters is further enhanced by an increased pump
flow, and therefore explains the only slight increase in URR. URR did not differ between
SL and DL catheters in the 3-hour dialysis for both the FV and CV position. In all cases
CV dialysis showed a higher URR than FV dialysis.
Based on our findings, for the longer lasting catheter dialysis, it is sensible to use the cen-
tral vein position, preferably the internal jugular vein, because of the reported increased
incidence of stenosis in the subclavian vein after catheter dialysis in that position [67].
However, when the catheter is needed for only a short amount of time, a SL femoral vein
catheter can also be considered. For example, when a vascular access graft or fistula clots
and a declot procedure can be planned within a few days.
Obviously, every effort must be made to minimize the use of temporary catheters. Not
only because of the lower adequacy of dialysis, when compared to other accesses. The
main indication for temporary catheter dialysis remains vascular access thrombosis.
With adequate surveillance techniques and timely intervention, it is possible to decrease
thrombosis rates. Also, timely planning of the permanent vascular access may lead to less
temporary catheters.
In conclusion, our data do not unequivocally support the preference for the DL catheter
for temporary hemodialysis access.
Coagulation and access thrombosis
An increased thrombotic tendency is an important cause of complications in patients on
chronic hemodialysis leading not only to possibly fatal complications like ischaemic
heart disease, or stroke, but also to thrombosis of the vascular access [68]. In most cases
thrombosis is associated with low access blood flow [25,69,70]. The most important rea-
son for a decreasing access blood flow is intimal hyperplasia formation at the venous
anastomosis or in the outflow tract of the graft [16-20,71]. However, not all decreases in
access blood flow are related to intimal hyperplasia or stenosis formation. Other causes
for low access flow leading to access thrombosis have been proposed. Hypotension, hypo-
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volaemia, or external compression may be involved in these non-stenotic thrombotic
events [13]. Also, there has been a growing appreciation of the role of increased hyperco-
agulability found in these patients.
In chapter 8 we discussed coagulability abnormalities in relation to haemodialysis access
thrombosis. Despite the bleeding tendency of chronic haemodialysis patients, vascular
access thrombosis is a frequent complication. Hypercoagulability is one of the causes
contributing to the high frequency of access thrombosis. The hypercoagulable state can
be explained by platelet and coagulation factor abnormalities. Unfortunately, few ran-
domized placebo-controlled trials were conducted using antiplatelet or oral anticoagula-
tion therapy. Therefore, no evidence-based consensus has been established regarding
pharmacological prevention of access thrombosis. It still needs to be determined whether
the potential benefits of anticoagulation and antiplatelet therapy outweigh the risk of
adverse events. In the meantime it seems reasonable to give some form of anticoagulant
therapy based on pathophysiological considerations and the high incidence of thrombot-
ic complications. Our group recently demonstrated that graft flow measurements could
effectively predict thrombotic vascular access events [72]. Risk tables that take into
account such parameters as well as plasma markers of hypercoagulability may help to
develop rationally designed trials and guidelines.
Future perspectives
Since the introduction of the AV fistula in 1966 and the PTFE AV graft a decade later, lit-
tle improvement has been made in the vascular access field [73,74]. Various variations on
both AV fistulae and grafts have been studied, but without much success [75]. The main
problem with today’s accesses is still thrombosis, mostly caused by intimal hyperplasia.
Several efforts have been made to decrease intimal hyperplasia. In experimental settings,
pharmacological interventions, improvement of biocompatibility, and influencing graft
geometry were quite promising in terms of inhibiting or reducing intimal hyperplasia. To
date however, none of these methods were successful in clinical studies [76]. Nonetheless,
future research is needed to inhibit intimal hyperplasia formation either pharmacologi-
cally or by improving biocompatibility.
Over more than 30 years people have tried to find the perfect vascular access. In my opin-
ion, this ideal access has the following characteristics: 1) easily constructable, 2) easily
accessible, 3) no intimal hyperplasia, 4) no infection, 5) no thrombosis, 6) limitless
patency, and 7) the ability to deliver a high dialysis dose. Unfortunately, this type of
access does not exist (yet). Several researchers have developed a device that can be totally
implanted under the pectoral skin [77]. This device has two lines connected to it that are
inserted into the subclavian vein. It can be accessed via needles through the skin.
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Hopefully, developments like these bring us more towards the ideal access.
However, a major objective over the coming years should be the widespread introduction
of access surveillance. Although the NKF-K/DOQI Committee on Vascular Access has
formed some recommendations on how to perform the most accurate surveillance, many
dialysis centers are still not putting this knowledge into practice [1]. With the developed
surveillance strategies, it is possible to decrease thrombosis rates dramatically [25]. With
regular access flow or venous pressure measurements and timely intervention, patency
rates will increase and, more importantly, patient care improves. Also, the treatment of
stenoses might be improved via direct evaluation of PTA by intra-procedural flow meas-
urement. That way it is possible to directly assess the effect of PTA. Another exiting new
development is the improved vascular access image quality of magnetic resonance imag-
ing [41]. All together this may lead to an efficient surveillance strategy which benefits all
that are involved in the dialysis care.
In summary, for the short-term it is important that every dialysis center not only has an
adequate surveillance strategy, but also a team that is dedicated to the vascular access.
This team should consist of a nephrologist, a vascular surgeon, a radiologist, and last but
certainly not least a nursing team. For the longer term, studies should be focused on
inhibiting intimal hyperplasia and thrombosis and on developing better accesses.
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Summary
Patients on hemodialysis require an access to their bloodstream. The Brescia-Cimino
(radio-cephalic) arteriovenous (AV) fistula is still regarded as the first choice for the cre-
ation of a vascular access for hemodialysis. Unfortunately, not all patients have suitable
vessels to construct an AV fistula. An alternative for the AV fistula is the polytetrafluo-
roethylene (PTFE) AV interposition graft. However, one of the major problems of these
AV grafts is a high thrombosis rate. This thesis focuses on the prevention and treatment
of hemodialysis access thrombosis.
There are various ways to monitor vascular accesses for impending failure: theoretically,
access flow (Qa) measurements provide more information about the vascular access than
the intra-access venous pressure (VP) measurement. In chapter 3 we investigated
whether Qa measurements are indeed better than VP measurements in identifying
patients at risk for thrombosis. Furthermore, we looked whether referral of patients for
percutaneous transluminal angioplasty (PTA) based on Qa measurements alone or on
the combination of VP and Qa reduces thrombosis rate more than referral based on VP
alone.
Magnetic resonance angiography (MRA) offers the opportunity to provide an image of
the access without the less desirable features of digital subtraction angiography (DSA).
However, because of turbulent blood flow some segments of the MR image can present
as a void, especially near the anastomoses. Even with contrast-enhancement there are still
substantial artifacts, because of the presence of flow. Therefore, we designed a flow-inter-
rupted contrast-enhanced MR imaging sequence. In chapter 4 we compared this novel
MRA imaging of the vascular access with DSA.
After detection of a failing access, it is important to intervene before thrombosis occurs.
The common approach for intervention nowadays is PTA. Several studies demonstrated
that the overall survival of the access can be prolonged by repetitive PTA. In chapter 5 we
studied the short-term effect of PTA on Qa, Qa patterns after PTA, and which factors had
an influence on Qa after PTA.
If, despite the efforts of detecting failing accesses timely, thrombosis still occurs, the dial-
ysis patient comes in an undesirable situation. Namely, the patient cannot get access to
the hemodialysis treatment. When this happens, it is paramount to re-establish a patent
vascular access as soon as possible. This can be done by surgical thrombectomy or radio-
logically by percutaneous thrombolysis. The latter has become the treatment of choice
for thrombosed hemodialysis grafts. In chapter 6 we compared three devices for percuta-
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neous thrombolysis with respect to their efficacy in removing thrombus from hemodial-
ysis access grafts.
Treatment should be initiated immediately after diagnosing thrombosis. In many cases
this cannot be done immediately and the patients rely on other types of accesses, mostly
a temporary catheter in the internal jugular or femoral vein. Basically, there are two types
of temporary catheters: the single-lumen and the double-lumen catheters. Single-lumen
catheters do not allow for a continuous blood flow to and from the dialysis machine,
whereas double-lumen catheters do. Although it is presumed that single-lumen catheters
have a lower dialysis adequacy than double-lumen catheters, this has not been formally
investigated yet. In chapter 7 we present a randomized prospective trial comparing dialy-
sis adequacy and overall performance in single-lumen versus double-lumen catheters.
Not all decreases in access blood flow are related to intimal hyperplasia or stenosis for-
mation. Other causes for low access flow leading to access thrombosis have been pro-
posed. Hypotension, hypovolaemia, or external compression may be involved in these
non-stenotic thrombotic events. Also, there has been a growing appreciation of the role
of increased hypercoagulability found in these patients. In chapter 8 we discuss coagula-
bility abnormalities in relation to haemodialysis access thrombosis.
Conclusions
1. Standardized monitoring of VP or Qa or the combination of both and subsequent
corrective intervention can decrease thrombosis rates to below 0.5 per patient-year,
which is recommended by the Vascular Access Task Force of the NKF-DOQI
Committee as quality of care standard. When applying the surveillance protocol, VP,
Qa, or the combination as variables for selection of patients for corrective interven-
tion are equally effective in reducing thrombosis rates in hemodialysis access grafts
(chapter 3).
2. Selective flow-interrupted CE-MRA imaging can provide excellent quality images of
hemodialysis AVF and AVG, which are free of flow artifacts. The high image quality
of the MR angiograms is comparable with DSA. In combination with MR flow quan-
tification and imaging of the outflow tract, our approach may provide a complete
anatomical and functional evaluation of hemodialysis accesses on MR (chapter 4).
3. Access flow increases after PTA, however in a substantial percentage not to a level
> 600 mL/min. Qa before PTA and the increase in Qa correlated with long-term out-
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come, whereas angiographic results did not. The present data combined with the lit-
erature suggest that there is an optimal timing for PTA (chapter 5).
4. In our evaluation of three mechanical devices used to declot thrombosed hemodialy-
sis access grafts, we found that the success of mechanical thrombolysis was deter-
mined more by the success of PTA of underlying stenoses than by the results of clot
removal. The rotating devices performed significantly better than the Hydrolyser in
removing thrombus from hemodialysis access grafts. The effectiveness of the two
rotating devices was comparable (chapter 6).
5. The use of double-lumen catheters as temporary access often results in better URR
than the use of singe-lumen catheters. However, differences obtained with single-
lumen catheters are limited, and, especially when only a limited number of dialysis
sessions are performed using catheters, of questionable clinical relevance. Also, many
catheter dialysis sessions will not result in adequate dialysis (chapter 7).
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Samenvatting
Bij hemodialyse is het noodzakelijk dat bloed van de patiënt naar het dialyse apparaat
gebracht wordt, daar gezuiverd wordt, en weer teruggebracht wordt van het apparaat
naar de patiënt. Om dit te bereiken heeft de patiënt een zogeheten toegang tot de bloed-
baan nodig, een vaattoegang. In veel gevallen is dit een zogeheten Brescia-Cimino fistel.
Dit is een verbinding tussen de slagader in de pols en een ader. Nadat de verbinding
gelegd is zal de ader in de loop van enkele weken uitzetten, zodat deze geschikt is om her-
haaldelijk aangeprikt te worden als vaattoegang. Helaas hebben lang niet alle patiënten
geschikte vaten om dit soort fistels te construeren. Een alternatief voor de directe fistel is
een vaatprothese die tussen de slagader en een ader geplaatst wordt, meestal in de elle-
boogsplooi. Deze vaattoegangen worden ook wel dialyse shunts genoemd. Eén van de
belangrijkste problemen van dialyse shunts is het ontstaan van vernauwingen, die kun-
nen leiden tot stolling van het bloed (trombose) in de vaattoegang, waardoor deze (tijde-
lijk) onbruikbaar wordt. Dit proefschrift gaat over het voorkomen en behandelen van
vaattoegang trombose.
Er zijn verschillende manieren om de vaattoegang in de gaten te houden voor wat betreft
het opsporen van aankomende trombose. Eén manier is om de hoeveelheid bloed te
meten die per tijdseenheid door een vaattoegang stroomt, ook wel bloedstroom
genoemd. Een andere veel gebruikte manier is om de druk te meten die het dialyse appa-
raat moet opbouwen om het bloed weer terug de vaattoegang in te pompen. Dit wordt
ook wel de veneuze drukmeting genoemd. Theoretisch gezien biedt de bloedstroom
bepaling meer informatie dan de veneuze druk meting bij het opsoren van vernauwin-
gen. In hoofdstuk 3 hebben we onderzocht of de bloedstroom bepaling inderdaad beter is
dan de veneuze druk meting bij het identificeren van patiënten die een hoog risico lopen
om een vaattoegang trombose te krijgen. Verder hebben we gekeken of er verschil was in
trombose frequentie tussen patiënten die verwezen waren voor een dotter behandeling
op grond van 1) de bloedstroom bepaling alleen, 2) de veneuze druk bepaling alleen, of
3) de combinatie van de bloedstroom bepaling en de veneuze druk meting. Het bleek dat
de trombose frequentie teruggebracht kon worden tot lager dan 0.5 per patiënt jaar na
een dotter behandeling op grond van het gestandaardiseerd meten van hetzij de veneuze
druk hetzij de bloedstroom hetzij de combinatie van deze twee. Met ons protocol van
vaattoegang bewaking is gebleken dat zowel de bloedstroom, als de veneuze druk, als de
combinatie hiervan als variabelen voor de selectie van patiënten voor een dotter behan-
deling de trombose frequentie in dezelfde mate omlaag kunnen brengen.
Magnetische resonantie angiografie (MRA) biedt de mogelijkheid om een afbeelding van
de vaattoegang te geven zonder de nadelen van de ‘normale’ röntgen angiografie (ook wel
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digitale subtractie angiografie genoemd, DSA). Echter, vanwege turbulentie in de bloed-
baan kunnen sommige segmenten van de MRA afbeelding zich voordoen als uitsparin-
gen in de afbeelding, zeker nabij de verbindingen van de vaten. Zelfs met MR contrast
zijn er nog steeds behoorlijke artefacten vanwege de bloedstroming. Daarom hebben we
een MRA meting ontwikkeld, waarbij de bloedstroom tijdelijk onderbroken wordt. In
hoofdstuk 4 hebben we deze nieuwe methode vergeleken met de conventionele DSA
afbeelding. Onze nieuwe methode bood afbeeldingen van uitstekende kwaliteit, vrij van
bloedstroom artefacten. De hoge kwaliteit van de MRA afbeeldingen was vergelijkbaar
met de DSA afbeeldingen. Een belangrijk voordeel van de MRA is dat hiermee ook de
bloedstroom gemeten kan worden. Hiermee zou onze benadering kunnen zorgen voor
een complete anatomische en functionele evaluatie van de vaattoegang met MRA.
Wanneer een slecht functionerende vaattoegang is gedetecteerd, is het belangrijk om in te
grijpen voordat trombose optreedt. De gangbare behandeling tegenwoordig is de dotter
behandeling, waarbij de vernauwing met een ballonnetje verholpen wordt. Verschillende
studies hebben aangetoond dat de levensduur van een vaattoegang kan worden verlengd
met herhaalde dotter behandelingen. In hoofdstuk 5 hebben we het korte en lange ter-
mijn effect bestudeerd van de dotter behandeling op de bloedstroom. Tevens hebben we
gekeken welke factoren van invloed waren op de bloedstroom na de dotter behandeling.
We vonden dat de bloedstroom toeneemt na de dotter behandeling, echter in een aan-
zienlijk percentage niet tot boven de 600 mL/min. De bloedstroom bepaling voor de dot-
ter procedure en de toename in bloedstroom correleerde met het lange termijn resultaat.
Het anatomische resultaat van de dotter procedure (m.a.w. de afname van de vernau-
wing) correleerde niet met het lange termijn resultaat. Onze gegevens gecombineerd met
gegevens van andere onderzoeken suggereren dat er een optimaal moment is voor een
dotter procedure.
Wanneer een vaattoegang stolt moet er snel een ontstopping ofwel trombolyse plaatsvin-
den. In hoofdstuk 6 worden drie apparaten voor trombolyse met elkaar vergeleken wat
betreft hun effectiviteit in het verwijderen van de trombose. De apparaten werkten op
verschillende manieren. Het eerste apparaat was een borsteltje dat letterlijk de binnenzij-
de van de vaattoegang schoon borstelt. Het volgende apparaat was een soort hoge druk
spuit die het stolsel in de vaattoegang vernevelt en opzuigt. Het derde apparaat was een
zelfontplooiend mandje dat zich tegen de binnenkant van het vat zet en zo het stolsel ver-
maalt en de binnenzijde van de vaattoegang schoon schraapt. Het schoonmaken van de
gestolde prothese lukte in vrijwel alle gevallen, maar de roterende apparaatjes die in
fysiek contact staan met de binnenzijde van de vaattoegang gaven de meest volledige ver-
wijdering van stolsels. Na het opruimen van de trombose werd de onderliggende vernau-
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wing gedotterd. De keuze van het soort apparaatje was niet van invloed op het lange ter-
mijn resultaat van de behandeling. Alleen het resultaat van de dotter behandeling bleek
de lange termijn resultaten te beïnvloeden. Dit toont aan dat een goede correctie van de
vaatvernauwing het belangrijkste onderdeel van de behandeling is.
In veel gevallen is het niet direct mogelijk om de getromboseerde vaattoegang weer te
openen. In dat geval is de patiënt afhankelijk van een ander soort vaattoegang. Dit is dan
meestal een tijdelijke catheter in één van de grote aders in de hals of lies. Er zijn twee
soorten tijdelijke catheters: catheters met een enkel lumen en catheters met een dubbel
lumen. Enkel-lumen catheters kunnen geen continue bloedstroom van en naar de dialyse
machine bewerkstelligen, terwijl dubbel-lumen catheters dit wel kunnen. Het wordt
daarom wel aangenomen dat enkel-lumen catheters een lagere dialyse effectiviteit berei-
ken dan dubbel-lumen catheters. Dit is echter nooit formeel onderzocht. In hoofdstuk 7
presenteren we een gerandomiseerde prospectieve trial waarbij we de dialyse effectiviteit
en de algehele prestatie hebben vergeleken tussen enkel- en dubbel-lumen catheters. We
vonden dat dubbel-lumen catheters beter in staat zijn om het beoogde bloedvolume te
verwerken dan enkel-lumen catheters. De effectiviteit van enkel-lumen catheters in een
lies ader verschilde niet met die van dubbel-lumen catheters in een lies ader. In een hals
ader was de effectiviteit van de dubbel-lumen catheter wel beter. Echter, veel dialyse ses-
sies met een catheter resulteerden niet in een effectieve dialyse. Bovendien waren de ver-
schillen tussen dubbel- en enkel-lumen catheters beperkt, en, zeker gezien de meestal
korte duur van de catheter dialyses, van twijfelachtige klinische relevantie.
Niet alle verminderingen van de bloedstroom zijn gerelateerd aan vaatvernauwingen.
Een lage bloeddruk, een laag circulerend volume, of externe compressie van de vaattoe-
gang zouden ook oorzaken voor een lage bloedstroom kunnen zijn. Er is tevens een
groeiende belangstelling voor de rol van de toegenomen stolbaarheid van het bloed bij
hemodialyse patiënten. In hoofdstuk 8 worden deze stollingsafwijkingen bij hemodialyse
patiënten besproken in relatie tot vaattoegang trombose.
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Dankwoord
Met veel genoegen kijk ik terug op de onderzoeksperiode die heeft geleid tot dit proef-
schrift. Veel mensen waren hier direct bij betrokken of hebben die periode op een andere
manier plezierig gemaakt. Allereerst wil ik de vele dialyse patiënten bedanken die meege-
werkt hebben met de onderzoeken die beschreven staan in dit proefschrift. Tevens wil ik
alle verpleegkundigen en radiologie laboranten bedanken die zeer behulpzaam en vol-
strekt onmisbaar waren bij het verzamelen van de gegevens.
Daarnaast wil ik een aantal mensen met name noemen.
Dr. P.J. Blankestijn, geachte co-promotor, beste Peter. Je kunde om zaken ten positieve te
keren is bewonderenswaardig. Als ik door de vele beschikbare data het overzicht even
verloor, wist jij er altijd zo’n draai aan te geven, dat alle stukjes weer snel in elkaar vielen.
Je vastberadenheid bij het analyseren van de data is indrukwekkend en soms vermoeiend,
maar leidde vrijwel altijd tot uitstekende resultaten. Het was erg leerzaam om met je te
hebben samengewerkt.
Drs. J. van der Linden, beste Joke. Een aanzienlijk deel van dit proefschrift is letterlijk
tevens van jou. Zonder de hulp van jou en Rene van den Dorpel bij het verzamelen en
analyseren van de nodige gegevens, had dit boekje er zeker anders uitgezien. De humor-
volle en relativerende gesprekken waren vaak een welkome afwisseling.
Prof. Dr. H.A. Koomans, geachte promotor, beste Hein. Misschien is de versnelde verou-
dering van hemodialyse patienten ook wel van invloed op de snelle proliferatie van inti-
ma hyperplasie in de vaattoegang. Ik weet het niet, maar in ieder geval heb ik van je de
waardevolle les geleerd om alles vanuit verschillende invalshoeken te bekijken.
Prof. Dr. W.P.Th.M. Mali. Bedankt voor het ter beschikking stellen van de MR tijd en
voor uw scherpe blik op het onderzoek.
Wil van der Mark, beste Wil. Hartelijk dank voor je hulp bij de onderzoeken. Weinig
mensen zijn meer geschikt om de resultaten in de praktijk te brengen en over Nederland
te verspreiden dan jij. Veel succes hiermee. Toen je me een e-mail liet zien van een thuis-
dialyse patiënt, die z’n eigen veneuze drukwaarden doormailde, kreeg ik echt het idee dat
we aan het begin stonden van een heel mooie nieuwe ontwikkeling.
Drs. C. Bos, beste Clemens, op weg naar de grenzen van de MR mogelijkheden en die dan
proberen te overschreiden. Het was een genot om daar deel van uit te maken. Je enthou-
siasme over de MR werkte erg aanstekelijk. Succes met jouw verdediging. Dr. C.J.G.
Bakker, beste Chris, wellicht kijken radiologen over 20 jaar terug naar onze tijd met jou
als boegbeeld voor de MR interventie. Maar dan moeten er eerst nog wel wat obstakels
uit de weg geruimd worden. Dr. H.F.M. Smits, beste Henk, als geen ander kun je mensen
motiveren. Je vertek was dan ook een groot gemis voor het vaattoegang onderzoek.
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Gelukkig was Dr. J.J. Zijlstra bereid om het houtje over te nemen. Beste Jan, parttime aca-
demisch radioloog, je komst zorgde al snel voor een frisse wind door het vaattoegang
onderzoek. Ook al was je maar een dag per week aanwezig, dit was vaak genoeg om ons
voor de rest van de week bezig te houden. Met je voortvarendheid kwam er in korte tijd
veel tot stand. De beste herinnering bewaar ik aan je opmerkelijke gevoel voor humor.
Dr. O.E.H. Elgersma, beste Otto, de combinatie met Jan werkte prima. Hij als perifeer
gangmaker en jij als academisch geweten.
Tineke en later Anneke van het trialbureau van de Radiologie, onmisbaar was jullie uiterst
efficiënte planning van de MRA en DSA onderzoeken. Ik kan iedere vakgroep een trial-
bureau aanraden, zeker met mensen zoals jullie. Cees Haaring, bedankt voor de database
ontwikkeling, andere computer ondersteuning, en de leerzame gesprekken over nieuwe
computersnufjes.
Verder wil ik Wilma van de angiokamer bedanken, niet in de laatste plaats voor haar uit-
stekende rol als beschermengel van eventueel toekomstig nageslacht als ik weer ‘ns een
loodschort als jas aantrok.
Collega-onderzoekers van de Nefrologie: Tycho, goede herinneringen heb ik aan de lun-
ches en vele gesprekken over van alles en nog wat. Oliver, soms dacht ik dat m’n verhalen
je wel moesten gaan vervelen, maar dit heb ik nooit gemerkt. Je verhalen waren bijzonder
en boeiend. Bedankt en veel geluk. Coes, eerst werd ik bijna geëlektrocuteerd als proef-
persoon bij je onderwater sympathicus onderzoek en nu bel je me regelmatig om zes uur
‘s ochtends uit bed om een pre-operatief onderzoek te doen. Toch zal ik je nu voor de
tweede keer gaan missen. Ingrid en Inge, niet-mis-te-verstane waarschuwingen van een
plaatselijke bewoner (“They’ll shoot you on the spot!”) weerhielden ons op het nippertje
om door Little Havana te fietsen. De andere tocht was zeker zo leuk. Jacobine, Thi Danh,
Diana, Simona, Jutta, succes met jullie onderzoek.
Collega’s van ziekenhuis Gooi-Noord: vanaf nu alleen de opleiding, gelukkig.
Walther, bedankt voor de introductie in het Nefrologie onderzoek. Verder Ronald, Gerry,
Branco, Jaap Beutler, Jaap Joles, Pieter, Menno, Brigitte, Peter Boer, Jaap Vos. Bedankt voor
de belangstelling en steun. Trees en Coby, zeer behulpzaam.
Alle participanten in de multi-center studies, hartelijk dank voor jullie deelname (in wil-
lekeurige volgorde): Dr E.C. Hagen, Dr. G.W. Feith, A. Diepenbroek, C.M. van der Beek,
M.M. Harskamp, E. van der Weele, Dr. G.M.Th. de Jong, Dr. J.H. Assink, D. Wolterbeek,
M.M. van Loon, Dr. H.H. Burger, Dr. E.F.H. van Bommel, Dr. M.I. Koolen, P.M. van der
Zee, L. van den Broek, Dr. B.J. Potter van Loon.
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Magne, vaak zorgde je voor de nodige afwisseling in de vorm van vakanties, uitstapjes en
huisfeesten. De waarde hiervan besefte ik pas echt toen je terug ging naar Noorwegen. Ik
hoop je nog vaak op de boerderij te komen bezoeken.
Harm en Sithabile, bedankt voor de interessante, maar nog vaker lachwekkende discussies
en voor de luisterende oren. S’tha, many thanks for the cover paintings.
Mijn broers, Edwin, Peter en Bart. Ik mocht maar twee paranimfen meenemen, maar het
liefst had ik jullie alledrie gevraagd. Bart, ben jij de volgende promovendus?
Beste ouders, met veel plezier denk ik terug aan de tijd op het Brabantse land aan de rand
van de Peel. Daar zijn de eerste schreden gezet op weg naar dit boekje. Zonder jullie was
dit niet mogelijk geweest. Moeder, ook al neemt je nauwgezetheid vaak verregaande vor-
men aan, soms hoop ik dat ik daarvan ook maar een klein deel heb meegekregen. Vader,
voorbeeld in nagenoeg alles. Ik denk dat ik namens m’n broers spreek, als ik zeg, dat we
zonder jullie motivatie, stimulatie en steun dit nooit hadden kunnen bereiken.
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behaalde het Gymnasium-β diploma in 1989 op het St.-Willibrord Gymnasium te
Deurne. Wegens uitloting voor de studie Geneeskunde werd hierna aangevangen met de
studie Fysiotherapie aan de Hogeschool Limburg te Heerlen. In 1990 werd hij alsnog
ingeloot voor de studie Geneeskunde, en wel aan de Universiteit Utrecht. Het doctoraal
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